AI Startups - 240

Corporations - 90
R&D Centers - 35
Investors - 600

FOR DRUG DISCOVERY,

BIOMARKER DEVELOPMENT
AND ADVANCED R&D LANDSCAPE
OVERVIEW 2020

DEEP
PHARMA
INTELLIGENCE

www.deep-pharma.tech
Table of Contents
AI for Drug Discovery Infographic Summary and Mind Maps 3 Introduction
Executive Summary 14 This 130-page “AI for Drug Discovery, Biomarker Development and
Advanced R&D Landscape Overview 2020” report marks the ninth
Pharma Efficiency: Challenges 16 installment in a series of reports on the topic of the Artificial Intelligence
Application of AI for Advanced R&D 18 (AI) application in pharmaceutical research industry that DKA Pharma
Division have been producing since 2017.
Business Activity 19
The main aim of this series of reports is to provide a comprehensive
AI in the global context 22 overview of the industry landscape in what pertains adoption of AI in
Top 50 AI for Drug Discovery Investors 23 drug discovery, clinical research and other aspects of pharmaceutical
R&D. This overview highlights trends and insights in a form of
AI for Drug Discovery Market Timeline 36 informative mind maps and infographics as well as benchmarks the
Pharma AI Deals performance of key players that form the space and relations within the
37
industry. This is an overview analysis to help the reader understand what
Corporation and AI-companies Participating in the Pharma AI Deals 39 is happening in the industry nowadays and possibly give an idea of what
Top 10 Leading Corporations by The Number of Major Pharma AI is coming next.
Deals 40 Substantial updates has been introduced since the previous edition,
which highlight fast-pacing industry dynamics, and overall growth of
Top AI and Tech Partners by the Number of Pharma AI Deals 41 investment and business development activity in the area of
Top AI Breakthroughs 2018-2020 42 pharmaceutical AI. The lists of AI-biotech companies, biotech investors,
and pharma organizations have been expanded to include new entities,
Computational Methods Used by the Most Advanced AI Companies 46 and a new list of leading contract research organizations (CROs) has
20 Notable R&D Use Cases of AI Application in Biopharma 55 been added to outline the growing interest of contract research industry
in the advanced data analytics technologies. We have also revisited data
Industry Developments 2020 95 and chapters from the last edition, and reflected on the changes that
Appendix: List of Entities 104 occured ever since.

Overview of Proprietary Analytics by Deep Pharma Intelligence Alongside investment and business trends, the report also provides
125
technical insights into some of the latest achievements in the AI
Disclaimer 130 application and research.
AI for Drug Discovery, Preclinical Clinical AI Companies - 240
Biomarker Development Development Development
Investors - 600
and Advanced R&D
Corporations - 90
Landscape / 2020

End-to-end Drug
Development Drug
Repurposing

AI Companies

Investors Pharma Tech

Corporations

CRO

Early And Preclinical

Drug Development

Early drug
development

DEEP
PHARMA
INTELLIGENCE
AI for Drug Discovery, Asia
AI Companies - 240
Biomarker Development
Investors - 600
and Advanced R&D Canada
Corporations - 90
Landscape / 2020

EU

China

AI Companies

Investors Pharma Tech

Corporations

Australia

CRO

US

UK
DEEP
PHARMA
INTELLIGENCE
Pharma AI Deals Structure 2020
Pharma Pharma
AI Companies Corporations
AI Companies
Corporations
Comparison of Top-32 Leading AI for Drug Discovery
Companies Expertise in Drug Discovery R&D / AI
Expertise in Drug Discovery

Clinical pipeline

Preclinical pipeline

Validated R&D Use cases

Advanced AI tools for a Advanced AI systems with End-to-end AI Platforms

specific Use Case multiple models

Expertise in AI
Deep Pharma Intelligence 6
 30 Leading Companies in AI for Drug Discovery Sector

1 A2A Pharma 16 DeepMind Health

2 AI Therapeutics 17 Envisagenics

3 Anima Biotech 18 Exscientia

4 Ardigen 19 healx
5 Atomwise 20 Insilico Medicine
6 Auransa 21 Insitro
7 BenevolentAI 22 Lantern Pharma
8 Berg 23 Nuritas
9 Bioage 24 Pharnext
10 biovista 25 Recursion Pharmaceuticals
11 BlackThorn Therapeutics 26 ReviveMed
12 Cyclica 27 Silicon Therapeutics
13 CytoReason 28 Turbine.AI
14 Deargen 29 twoXAR
15 Deep Genomics 30 XtalPi

Deep Pharma Intelligence 7

 240 AI Companies: Regional Proportion

Canada 6.7% UK 14.2%

EU 13.4%

US 54.4%
China 2.5%
Australia 0.4%

Asia 8.4%

The US is still firmly in the lead in terms of its proportion of AI for Drug Discovery companies. Interestingly, Asia currently has the fifth-lowest
proportion of AI for Drug Discovery companies. However, Asia-Pacific region has begun to aggressively increase its activity in the space in terms of
investments into foreign companies (largely US-based companies), and we expect to see an increase in the number of AI for Drug Discovery
Companies located in the Asia-Pacific region generally, and in China particularly.

Deep Pharma Intelligence 8

 600 Investors: Regional Proportion

Canada 2.53% UK 8.75%

EU 13.5%

Asia 8.92%
US 64.9%
China 1.35%

The United States continues to lead the rest of the world in terms of artificial intelligence for companies and funds that invest in Drug Discovery. This
is reasonable, given that more than a half of the world’s AI for Drug Discovery companies have their headquarters in USA. Comparing with previous
periods of 2020, we can observe significant growth of the number of investors in the USA and EU. Thus, together with UK these regions are leaders by
the number of investors in AI in Drug Discovery companies.

Deep Pharma Intelligence 9

 20 CROs: Regional Proportion

UK 10%

EU 30%

US 55%
China 5%

The United States leads the AI race on the level of Contract Research Organizations as well, with 55% of CROs being based in the US. It is followed by
the European Union with around 30%. The other 10% have their headquarters in the UK. China represents only 5% of the AI-interested CROs, which
would probably increase in the following years due to Chinese strategy on AI implementation and large investments in the AI industry.

Deep Pharma Intelligence 10

 35 Leading R&D Centers: Regional Proportion

UK 8.6%

EU 31.4%

US 37.1%
China 5.7%

Asia 17.2%

Following the trend from our previous reports the map indicates that the US leads the world in terms of the number of R&D Centers focused on AI for
Drug Discovery. This is sensible within the context of the recent increase in the number of investors that invest in AI for Drug Discovery space within
the territory of United States. The same trend can be observed in European Union as it demonstrates second biggest figure of investors’ part in the
world that results in second biggest share of Leading R&D Centers.

Deep Pharma Intelligence 11

 30 Pharma Corporations Applying Advanced AI in Healthcare and Drug Discovery

UK 7% Switzerland 7%

EU 23%

US 40%

Asia 23%

The industry is seeing an increasing level of regional diversification. Whereas historically the US has dominated the AI for Drug Discovery race in
terms of the number of AI companies, the volume of investments and number of industry specialized conferences, in 2019 we are seeing an
increased level of activity from the UK, Switzerland and China.

Deep Pharma Intelligence 12

 40 Leading Tech and Chemical Corporations: Regional Proportion

Switzerland 5%

EU 20%

US 45%
China 10%

Asia 20%

The US is the leader according to the number of tech corporations applying advanced AI in healthcare and drug discovery. EU leads the world in terms
of the number of Chemical Corporations. The second biggest figure can be observed in Asia while the US is in the third place. This is sensible within
the context of the recent increase in the chemical industry in EU that overweight the US and Asian markets of chemical substances and related
products. A lot of these chemical corporations are participating in cooperations and partnerships that are aimed at drug discovery and are related to
pharmaceutical issues.

Deep Pharma Intelligence 13

Executive Summary

DEEP
PHARMA
INTELLIGENCE
This Report at a Glance
This 130-page “AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape Overview 2020” report marks the ninth installment in a
series of reports on the topic of the Artificial Intelligence (AI) application in pharmaceutical research industry that DKA Pharma Division have been
producing since 2017.
The main aim of this series of reports is to provide a comprehensive overview of the industry landscape in what pertains adoption of AI in drug
discovery, clinical research and other aspects of pharmaceutical R&D. This overview highlights trends and insights in a form of informative mind maps
and infographics as well as benchmarks the performance of key players that form the space and relations within the industry. This is an overview
analysis to help the reader understand what is happening in the industry nowadays and possibly give an idea of what is coming next.
Substantial updates has been introduced since the previous edition, which highlight fast-pacing industry dynamics, and overall growth of investment
and business development activity in the area of pharmaceutical AI. The lists of AI-biotech companies, biotech investors, and pharma organizations
have been expanded to include new entities, and a new list of leading contract research organizations (CROs) has been added to outline the growing
interest of contract research industry in the advanced data analytics technologies. We have also revisited data and chapters from the last edition, and
reflected on the changes that occured ever since.
Alongside investment and business trends, the report also provides technical insights into some of the latest achievements in the AI application and
research.

This report has been put together taking into account the unprecedented global COVID19 pandemics, which substantially
impacted every industry on the planet, pharma and biotech not being an exception. Quite expectedly, COVID19 brought about
quite a few opportunities for the drug makers and vaccine developers and in general, it catalyzed more rapid progress in the
pharmaceutical AI space as well. Not only a lot of AI-assisted drug repurposing programs have been launched in first half of
2020, but also the research environment has become more collaborative, with lots of open science project, and numerous
companies opening free access to their platforms. However, COVID19 also created major challenges for the pharma industry,
such as disruptions in clinical trials and regular research projects and lab workflows. However, our findings related to COVID19
impact on the biotech investment landscape will be presented in the upcoming report, dedicated specifically to this issue.

Deep Pharma Intelligence 15

 Pharma Efficiency: Challenges > 10 years
>$2.6 bln
1 new drug
Drug 10, 000 compounds
discovery It takes on average over 10 years to bring a new drug
to market. As of 2014, according to Tufts Center for
the Study of Drug Development (CSDD), the cost of
developing a new prescription drug that gains market
Pre-clinical 250
development approval is approximately $2.6 billion. This is 145%
compounds
increase, correcting for inflation, comparing to the
same report made in 2003.
Clinical
development 0 - Effect on body The pharmaceutical industry is in a terminal decline,
5 I - Safety in humans
and the returns on new drugs that do get to market do
II - Effectiveness at treating
diseases not justify the massive investments that Pharma
III - Larger scale safety and currently puts into R&D anymore.
effectiveness
Regulatory approval IV - Long term safety
FDA The solution to this problem comes from three key
strategies:
-- evolution of business models towards more
Result collaboration and pipeline diversification early.
-- implementation of AI as a universal shift towards
1 approved drug
data-centric drug discovery
-- Discovery of new therapeutic modalities (biologics,
Source Endpoints News ePharmacology
therapies etc)
Deep Pharma Intelligence 16
 The pharmaceutical AI sector is “heating up”

In this report we have profiled 240 actively Big Pharmas active in

developing AI-driven biotech startups, adding some AI-focused partnerships
40 companies since our 2019 edition. A steady
growth in the “AI for Drug Discovery sector” can be 8 Deals
observed in terms of substantially increased amount
of venture capital pouring into the AI-driven biotech
startups (around $1.9B in 2020 alone, so far), the 7 Deals
increasing number of research partnerships between
leading pharma organizations and AI-biotechs, and
AI-technology vendors, a continuing pipeline of
6 Deals
industry developments, research breakthroughs, and
proof of concept studies, as well as exploding
attention of leading media and consulting companies
to the topic of AI in pharma and healthcare.
Some of the leading pharma executives increasingly 4 Deals
see AI as not only a tool for lead identification, but
alos a more general tool to boost biology research
and identify new biological targets and develop novel
disease models.
The main focus of AI research for today is still on 3 Deals
small molecules as a therapeutic modality.

Deep Pharma Intelligence 17

 Application of AI for Advanced R&D to Address Pharma Efficiency Challenges

Target Discovery and Early Drug Discovery Design and Processing of Preclinical Experiments
● Analyze data sets, form hypotheses and generate novel insights ● Reduce time, money, and uncertainty in planning experiments
● Identify novel drug candidates ● Decode open- and closed-access data on reagents and get
● Analyze data from patient samples in both healthy and diseased actionable insights
states to generate novel biomarkers and therapeutic targets ● Automate selection, manipulation, and analysis of cells
● Predict binding affinity and other pharmacological properties of ● Expedite development of cell lines and automate manufacturing of
molecules cellular therapeutics
● Allow filtering for drug-like properties of molecules ● Automate sample analysis with a robotic cloud laboratory
● Reduce complexity in protein design
Repurposing of Existing Drugs
● Rapidly identify new indications for many known drugs
Clinical Trials ● Match existing drugs with rare diseases
● Optimize clinical trial study design ● Conduct experimental biology at scale by testing 1000+ of
● Transform diverse streams of biomedical and healthcare data compounds on 100+ of cellular disease models in parallel
into computer models representative of individual patients ● Generate novel biomarkers and therapeutic targets
● Deliver personalized medicine at scale by revealing optimal health
interventions for individual patients
Aggregation and Synthesis of Information
● Analyze medical records to find patients for clinical trials
● Automate matching cancer patients to clinical trials through ● Extract knowledge from literature
personal medical history and genetic analysis ● Generate insights from thousands of unrelated data sources
● Improve pathology analysis ● Improve decision-making
● Identify patients that would benefit from novel therapies ● Eliminate blind spots in research
● Identify competitive whitespace

Deep Pharma Intelligence 18

 Business Activity
The business activity has been increasing in the pharmaceutical AI space over 2020, judging by an increased number of transactions and partnership
announcements in this period.
The most significant deals and collaborations in 2020 include:
● XtalPi — SoftBank Vision Fund 2, PICC Capital, and MorningSide Venture Capital: XtalPi has raised $319M in funding round C. The funding will
be used for the further development of XtalPi’s Intelligent Digital Drug Discovery and Development (ID4) platform.
● AstraZeneca intends to open AI and drug research centers in China and make a $1 billion capital infusion into Chinese biotech innovations.
● Exscientia — Bayer: Exscientia has entered a 3-year $266 million agreement with Bayer. The partnership will leverage AI to accelerate the
discovery of small molecules candidates programs for oncology and cardiovascular diseases.
● Schrödinger — Bayer: Schrödinger has entered a 5-year agreement with Bayer to work on a new virtual platform for small molecules design,
which will be able to design and screen synthetically feasible compounds.
● Schrödinger — Google Cloud: Schrödinger enters a 3-year collaboration with Google Cloud to leverage the supercomputer power for speeding
up Schrödinger’s molecular modeling platform.
● Boehringer Ingelheim — BERG: Boehringer Ingelheim partners with BERG to investigate inflammatory diseases, particularly inflammatory bowel
disease and Crohn’s disease, find the causes, develop new biomarkers, targets, and new drugs.
● Global Open Science project COVID Moonshot was launched by the international consortium of industrial and academic partners, including
AI-driven startup PostEra.
● Insitro — Andreessen Horowitz, Canada Pension Plan Investment Board: insitro, a machine learning-driven drug discovery company, has raised
$143 million in Series B financing. The investment will be used to further develop the company's technology and automation.
Partnerships like these provide a huge effect on Pharma industry and are needed in case if a company intends to become a leader in the ongoing
competition.

Deep Pharma Intelligence 19

 Major Observations for 2020: Key Business Takeaways

1. The segment of pharmaceutical AI continues consolidation with the increasing number of later stage mega-rounds, including those of
Insitro (), Recursion Pharmaceuticals, XtalPi and others. The AI startups pack is clearly differentiating into the leaders, who developed
substantial resources, financial leverage, and technological advantage, and others lagging behind -- companies with less resources or less
mature technology and scientific assets. The latter are usually focused on narrow therapeutic or technological niches, and are following
service-oriented business models.
2. Pharmaceutical AI sector is “heating up”, and becomes a lucrative area for specialized biotech investors as well as investor organizations
just entering the pharma space with a goal of including high-risk/high-return companies in their investment portfolios. This is backed by
several observations, including an overall increasing investment activity in this sector in 2020, the increasing rush among leading pharma
and contract research organizations (CROs) to compete for partnerships with AI-driven companies, and the increasing amount of
proof-of-concept breakthroughs, confirming that AI technology has achieved substantial maturity to be able to bring tangible value for drug
discovery -- far beyond a simple optimization gain.
3. Big pharma and contract research organizations increasingly compete for AI partnerships, and continue building in-house AI
workflows -- driven by rapidly emerging evidence of the AI tech feasibility and innovation potential. A number of highly notable
proof-of-concept results has been announced in 2019-2020.
4. COVID-19 pandemics appears to be a positive catalyst for the acceleration of the AI adoption by the pharmaceutical organizations.
This is primarily stipulated by the necessity to rapidly process vast amounts of data, and come up with innovations under strict deadlines.
Therefore, this urgency pushed companies and investors into more opportunistic projects than ever before.

Deep Pharma Intelligence 20

 Key Technology Takeaways Obstacles That Still Remain

1. AI is regarded by some top executives at big pharma (GSK 1. Global shortage of AI talent continues to be a serious challenge
and others) as a tool to uncover not only new molecules, but for the biopharma industry, repeating the trend from our previous
also new targets. Ability of deep neural networks to build reports. While big pharmaceutical companies invest substantial
ontologies from multimodal data (e.g. “omics” data) is capital in recruitment of AI specialists, still the majority of them are
believed to be among the most disruptive areas for AI in drug acquired by large tech corporations (Google, Amazon, Alibaba,
discovery, alongside with data mining from unstructured data, Tencent, Baidu etc.) However, a growing wave of specialized
like text (using natural language processing, NLP). university programs and courses, geared towards data science and
AI application, is projected to address this issue to certain extent in
2. There is a considerable trend for “AI democratization” where the coming years.
various machine learning/deep learning technologies become
available in pre-trained, pre-configured “of-the-shelf” formats, 2. Lack of available quality data is still a challenge for the
or in relatively ready-to-use formats -- via cloud-based models, unleashing full potential of deep learning technologies. Numerous
frameworks, and drag-and-drop AI-pipeline building platforms variations of deep learning (DL) are believed to be the most
(for example, KNIME). This is among key factors in the lucrative area of AI for applications such as drug discovery and
acceleration of AI adoption by the pharmaceutical clinical research. The key challenge is that DL algorithms are
organizations -- where a non-AI experts can potentially use “data-greedy”, while big data in biotech is not always well-versed
fairly advanced data analytics tools for their research. for modeling, or is inaccessible due to privacy reasons.

3. Proof-of-concept projects keep yielding successful results -- 3. Ethical, legal, and regulatory issues for AI adoption in the
in research studies, and in the commercial partnerships alike. pharmaceutical sciences. This set of challenges is related to the
For example, companies like Recursion Pharmaceuticals and previous point, but also includes other questions -- AI explainability,
Exscientia achieved important research milestones using their patentability of AI-generated results, non-optimal regulations in
AI-based drug design platforms. various countries, slowing down the progress and adoption of AI
technologies in general, and in the pharmaceutical industry in
particular.
Deep Pharma Intelligence 21
 AI in the global context
US is a main player in AI industry. In the beginning of AI implementation, US was a pioneer and then the main player with the greatest number of
companies using AI to force R&D, research centres and institutes, and investments. However, we observe the increased level of the UK and EU activity
through big corporations that use AI to reorganise drug discovery and in launching government initiatives. It is also important to note a great increase
in activity from the Asia-Pacific region generally, and particular from China — AI superpower.
China engages in extensive investment activity. In particular, it has promised to invest $5 billion in AI. Tianjin, one of the biggest municipalities, is
going to invest $16 billion in its local AI industry, and the Beijing authorities will build $2.12 billion AI development project. China also has at least ten
privately owned AI startups valued at more than US$1 billion. Moreover, China has been heavily investing in biotech R&D, although lately a serious
decrease in Chinese investment in US biotech startups has been observed which can be explained by the trade conflicts between the US and China.
China plans to become the world AI leader by 2030, according to the AI Strategic Plan released in July 2017. The analysis of the the Asia-Pacific
region has shown that the main forcers of AI implementation include Saama Technologies, Inc., a leading clinical data analytics company. It has
announced a collaboration with researchers at the Tufts Center for the Study of Drug Development to ascertain how biopharmaceutical companies
optimize automation and information technologies, including machine learning and neural networks, to support the research and development of new
therapeutics. Moreover, XtalPi provides a huge number of talent to work with machine learning, create drug discovery and development applications
that predict the properties of small molecules. Another innovators of Asian AI industry are Cytlimic and Fujitsu that offer software for predicting how
well compounds will bind with each other and proteins.
Europe has traditionally been a strong breeding ground for biopharma activity, with some recent large valuations and mega deals. The UK and EU
activity in the pharmaceutical AI race is mainly boosted by Novartis that announced an important step in reimagining medicine by founding the
Novartis AI innovation lab and by selecting Microsoft Corp. as its strategic AI and data-science partner for this effort. Furthermore, GlaxoSmithKline
has announced a few deals with companies such as Exscientia, Insilico Medicine, Insilico Biotechnology to use new computer modelling systems.
BenevolentAI, a global leader in the application of AI for scientific innovation, also has several high-profile research collaborations, including
AstraZeneca, and licensed in a group of drugs to develop from Janssen in 2016. This all demonstrate that Pharma is increasingly turning to AI to
transform the drug discovery process.

Deep Pharma Intelligence 22

Pharmaceutical AI Sector
is “Heating Up”:

Top 50 AI for Drug

Discovery Investors

DEEP
PHARMA
INTELLIGENCE
 Investment landscape at a glance (Q4 2019 — 2020)
The total amount of VC funding in AI-biotech startups increased in
2020 (as of November) by around 23%, compared to 2019,
approaching a total of $1.9B, which is also more than in 2015, 2016
and 2017 combined.

There is an increasing number of late-stage mega-rounds (e.g. B, C),

including hundreds of millions. The apparent trend is sector
consolidation, where a number of AI-startups have achieved
substantial leadership and grown in resources and technology, while
others have lagged behind and had to focus on niche service-oriented
segments of drug discovery. Several AI startups also went out of
business.

Some of the major deals included:

● insitro with their $143 million (Series B);
● XtalPi with $319 million (Series C);
● Atomwise with $123 million (Series B);
● Recursion Pharmaceuticals with $239 million (series D);
● AbCellera with the sum of $105 million (Series B).
An important driver of growth for the sector is a substantial shift in Big
Pharma’s interest in AI technology from “nice to try” to “strategically
important”. Such increasing market demand will drive more exits in
future, and is important for heating up the investor’s interest in this
sector.

Deep Pharma Intelligence 24

 50 Leading Investors in AI for Drug Discovery Sector

1 GV 16 Third Rock Ventures

2 Casdin Capital 17 ZhenFund
3 Creative Destruction Lab 18 500 Startups
4 Y Combinator 19 Bill & Melinda Gates Foundation
5 Alexandria Venture 20 Celgene
6 WuXi AppTec 21 Data Collective DCVC
7 Andreessen Horowitz 22 F-Prime Capital
8 EASME - EU Executive Agency for SMEs 23 Foresite Capital
9 Lilly Asia Ventures 24 Founders Fund

10 OS Fund 25 Inovia Capital

11 AME Cloud Ventures 26 Intel Capital

12 ARCH Venture Partners 27 Khosla Ventures

13 Felicis Ventures 28 Perceptive Advisors

14 National Institutes of Health 29 SoftBank Vision Fund

15 StartX (Stanford-StartX Fund) 30 UK Innovation & Science Seed Fund

Deep Pharma Intelligence 25

 50 Leading Investors in AI for Drug Discovery Sector

31 8VC 41 Mubadala Capital | Ventures US

32 Alexandria Real Estate Equities 42 Nextech Invest
33 Vertex Ventures 43 Obvious Ventures
34 Atlas Venture 44 Qiming Venture Partners
35 Baidu Ventures 45 RA Capital Management
36 Baillie Gifford 46 Refactor Capital
37 General Catalyst 47 Sequoia Capital
38 IA Ventures 48 SOSV
39 Johnson & Johnson Innovation 49 Tencent Holdings

40 Luminous Ventures 50 Two Sigma Ventures

Deep Pharma Intelligence 26

 Top-50 AI for Drug Discovery Investors
Alexandria Real Estate
Equities 8VC Tencent Holdings
San Francisco, California, US Shenzhen, China
Pasadena, California, US
China
Intel Capital Founders Fund
San Francisco, California, US
Santa Clara, California, US

Refactor Capital Foresite Capital

Burlingame, California, US San Francisco, California, US

Other 500 Startups Canada

San Francisco, California, US
Beijing Shanghai
WuXi
Alexandria Venture ZhenFund
Sequoia Capital Beijing, China AppTec
Menlo Park, California, US San Francisco, California, US Shanghai, China
Perceptive Advisors Inovia Capital Baidu Ventures Lilly Asia Ventures
Obvious Ventures Montréal, Quebec, Canada
Andreessen Horowitz San Francisco, California, US
New York, New York, US Beijing, China Shanghai, China
Menlo Park, California, US
Creative Destruction
Data Collective DCVC IA Ventures Lab Qiming Venture Partners
Felicis Ventures San Francisco, California, US New York, New York, US Toronto, Ontario, Canada Shanghai, China
Menlo Park, California, US
Mubadala Capital |
Ventures US Two Sigma Ventures
New York, New York, US EASME - EU Executive Agency
Khosla Ventures San Francisco, California, US
Menlo Park, California, US Belgium for SMEs Switzerland Nextech Invest
San Francisco Casdin Capital Brussels, Brussels Hoofdstedelijk Zürich, Zurich, Switzerland
Menlo Park New York, New York, US Gewest, Belgium

New York
California
Massachusetts
United States
Palo Alto Atlas Venture
Other States Cambridge, Massachusetts, US
StartX Bill & Melinda Gates SoftBank Vision Fund
Palo Alto, California, US
Foundation General Catalyst London, England, United Kingdom
Cambridge, Massachusetts, US
Seattle, Washington, US
AME CLoud Ventures Amadeus Capital Partners
Palo Alto, California, US Lili Ventures London, England, United Kingdom
Indianapolis, Indiana, US SR One
Illinois Cambridge, Massachusetts, US
Vertex Ventures
Baillie Gifford
Palo Alto, California, US SOSV Edinburgh, Edinburgh, United Kingdom
OS Fund Princeton, New Jersey, US Third Rock Ventures
Mountain View Park Ridge, Illinois, US
Celgene
Boston, Massachusetts, US
United UK Innovation & Science Seed Fund
Y Combinator ARCH Venture Partners Summit, New Jersey, US F-Prime Capital Kingdom Harwell, Oxfordshire, United Kingdom

Mountain View, California, US Chicago, Illinois, US National Institutes of Cambridge, Massachusetts, US

Health Luminous Ventures
London, England, United Kingdom
GV Bethesda, Maryland, US RA Capital Management
Mountain View, California, US Johnson & Johnson Boston, Massachusetts, US
Innovation
New Brunswick, New Jersey, US
Deep Pharma Intelligence 27
 Dynamics of Investments (in millions of USD per year)

Source: BioPharmaTrend
Deep Pharma Intelligence 28
50 Leading Investors Portfolios of leading
AI in Drug Discovery (Part 1) biotech investors
include startups from
the list of Top 30

Other AI Companies

Investors

Top-30 AI
Companies

DEEP
PHARMA
INTELLIGENCE
50 Leading Investors Portfolios of leading
AI in Drug Discovery (Part 2) biotech investors
include startups from
the list of Top 30

Other AI Companies

Investors

Top-30 AI
Companies

DEEP
PHARMA
INTELLIGENCE
Top-50 Investors in AI Companies
INVESTORS AI Companies Investments overall

Alector, BlackThorn Therapeutics, Celsius Therapeutics, Flatiron Health, Foundation

13 AI for Drug Discovery
GV Companies
24 Medicine, Gritstone Oncology, Ideaya Biosciences, Insitro, Relay Therapeutics, Owkin,
Schrödinger, Strateos, ZappRx

10 AI for Drug Discovery Alector, Arzeda, Celsius Therapeutics, Flatiron Health, Foundation Medicine, Gritstone
Casdin Capital Companies
11 Oncology, Insitro, Neon Therapeutics, Recursion Pharmaceuticals, Relay Therapeutics

Creative 10 AI for Drug Discovery Atomwise, BenchSci, Biotx.ai, Deep Genomics, Entropica Labs, Kyndi, NetraMark,
Companies
10
Destruction Lab Phenomic AI, ProteinQure, WinterLight Labs

9 AI for Drug Discovery Athelas, Atomwise, Cambridge Cancer Genomics, CloudMedX, PostEra, Reverie Labs,
Y Combinator Companies
14 Strateos, uBiome, Verge Genomics

8 AI for Drug Discovery Relay Therapeutics, TARA Biosystems, BlackThorn Therapeutics, Celsius Therapeutics,
Alexandria Venture Companies
11
GNS Healthcare, Gritstone Oncology, Ideaya Biosciences, Insitro

7 AI for Drug Discovery

WuXi AppTec Companies
8 Engine Biosciences, Insilico Medicine, Insitro, Schrödinger, Strateos, Verge Genomics,
Ideaya Biosciences

Andreessen 6 AI for Drug Discovery

Companies
9 BioAge Labs, Erasca, Flatiron Health, Insitro, TwoXAR, uBiome
Horowitz
EASME - EU
6 AI for Drug Discovery
Executive Agency Companies
6 Accutar Biotech, Cytox, Genialis, Iris.ai, Mind the Byte, omicX
for SMEs
6 AI for Drug Discovery Alector, Gritstone Oncology, Insilico Medicine, Just Biotherapeutics, Nimbus Therapeutics,
Lilly Asia Ventures Companies
9
Numerate

6 AI for Drug Discovery Arzeda, Atomwise, Emerald Cloud Lab, TwoXAR, uBiome, Verge Genomics
OS Fund Companies
9

Deep Pharma Intelligence 31

Top-50 Investors in AI Companies
INVESTORS AI Companies Investments overall

AME 5 AI for Drug Discovery Atomwise, BioAge Labs, Cambridge Cancer Genomics, Recursion Pharmaceuticals,
Companies
11
Cloud Ventures Strateos

ARCH 5 AI for Drug Discovery

Companies
10 Arbor Biotechnologies, BlackThorn Therapeutics, Erasca, Insitro, Just Biotherapeutics
Venture Partners

5 AI for Drug Discovery BioAge Labs, LabGenius, ProteinQure, Recursion Pharmaceuticals, Spring Discovery
Felicis Ventures Companies
10

National Institutes 5 AI for Drug Discovery

Companies
6 Envisagenics, Recursion Pharmaceuticals, Sangamo BioSciences, SEngine Precision
of Health Medicine, Virvio

StartX (Stanford- 5 AI for Drug Discovery Bioz, Globavir Biosciences, NuMedii, TwoXAR, uBiome
Companies
7
StartX Fund)
Third Rock 5 AI for Drug Discovery
Companies
11 Celsius Therapeutics, Foundation Medicine, Insitro, Neon Therapeutics, Relay Therapeutics
Ventures

5 AI for Drug Discovery

ZhenFund Companies
8 Deep Intelligent Pharma, Spring Discovery, uBiome, Xbiome, XtalPi

Sequoia 5 AI for Drug Discovery

Companies
8 Athelas, Berkeley Lights, Deep Intelligent Pharma, PatSnap, XtalPi
Capital China
Bill & Melinda Gates 4 AI for Drug Discovery
Companies
5 Atomwise, Just Biotherapeutics, Recursion Pharmaceuticals, Schrödinger
Foundation

4 AI for Drug Discovery Arrakis Therapeutics, Exscientia, GNS Healthcare, Ideaya Biosciences
Celgene Companies
5

Deep Pharma Intelligence 32

Top-50 Investors in AI Companies
INVESTORS AI Companies Investments overall

Data Collective 4 AI for Drug Discovery

Companies
12 Atomwise, Frontier Medicines, Recursion Pharmaceuticals, Strateos
DCVC
4 AI for Drug Discovery
F-Prime Capital Companies
5 BenchSci, Insilico Medicine, Notable, Owkin

4 AI for Drug Discovery

Foresite Capital Companies
10 Alector, Insitro, Juvenescence AI, Relay Therapeutics

4 AI for Drug Discovery

Founders Fund Companies
6 Datavant, Emerald Cloud Lab, Roivant Sciences, Strateos

4 AI for Drug Discovery

Inovia Capital Companies
7 BenchSci, LabGenius, Phenomic AI, ProteinQure

4 AI for Drug Discovery

Intel Capital Companies
4 Healx, Kyndi, Reveal Biosciences, VERISIM Life

4 AI for Drug Discovery

Khosla Ventures Companies
8 Atomwise, BioAge Labs, Deep Genomics, ThoughtSpot

4 AI for Drug Discovery

Perceptive Advisors Companies
4 Alector, Ideaya Biosciences, Relay Therapeutics, Saama

SoftBank 4 AI for Drug Discovery

Companies
5 Datavant, Relay Therapeutics, Roivant Sciences, XtalPi
Vision Fund

UK Innovation & 4 AI for Drug Discovery Antiverse, Cytox, Desktop Genetics, Synthace
Companies
6
Science Seed Fund

Deep Pharma Intelligence 33

Top-50 Investors in AI Companies
INVESTORS AI Companies Investments overall

4 AI for Drug Discovery Notable, PathAI, ProteinQure, uBiome

8VC Companies
6

Alexandria 4 AI for Drug Discovery Arbor Biotechnologies, BlackThorn Therapeutics, GNS Healthcare, Ideaya Biosciences
Companies
5
Real Estate Equities
4 AI for Drug Discovery
500 Startups Companies
5 Massive Bio, Strateos, uBiome, BenchSci

3 AI for Drug Discovery Atomwise, Engine Biosciences, Insilico Medicine

Baidu Ventures Companies
4

3 AI for Drug Discovery Flatiron Health, Recursion Pharmaceuticals, Tempus

Baillie Gifford Companies
5

3 AI for Drug Discovery

General Catalyst Companies
6 PathAI, Spring Discovery, ThoughtSpot

Vertex 3 AI for Drug Discovery

Companies
6 Nucleai, PatSnap, BlackThorn Therapeutics
Ventures
3 AI for Drug Discovery
IA Ventures Companies
4 Flatiron Health, Strateos, Verge Genomics

Johnson & Johnson 3 AI for Drug Discovery Aetion, BlackThorn Therapeutics, Datavant
Companies
4
Innovation

3 AI for Drug Discovery Phenomic AI, Sparrho, Synthace

Luminous Ventures Companies
4

Deep Pharma Intelligence 34

Top-50 Investors in AI Companies
INVESTORS AI Companies Investments overall

Mubadala Capital | 3 AI for Drug Discovery

Companies
5 Insitro, Owkin, Recursion Pharmaceuticals
Ventures US
3 AI for Drug Discovery
Nextech Invest Companies
4 Arrakis Therapeutics, Ideaya Biosciences, Neon Therapeutics

3 AI for Drug Discovery

Obvious Ventures Companies
8 Inato, LabGenius, Recursion Pharmaceuticals

Qiming Venture 3 AI for Drug Discovery

Companies
3 Insilico Medicine, Schrödinger, ZappRx
Partners
RA Capital 3 AI for Drug Discovery
Companies
3 Frontier Medicines, iTeos Therapeutics, Nimbus Therapeutics
Management
3 AI for Drug Discovery
Refactor Capital Companies
4 Cambridge Cancer Genomics, PathAI, Verge Genomics

3 AI for Drug Discovery Nimbus Therapeutics, Numerate, ZappRx

Atlas Venture Companies
9

3 AI for Drug Discovery

SOSV Companies
10 A2A Pharmaceuticals, MendelAI, Synthace

3 AI for Drug Discovery

Tencent Holdings Companies
6 Atomwise, iCarbonX, XtalPi

Two Sigma 3 AI for Drug Discovery Recursion Pharmaceuticals, Verge Genomics, Antiverse
Companies
5
Ventures

Deep Pharma Intelligence 35

 AI for Drug Discovery Market Timeline
● The first scalable AI approaches for Drug Discovery and Advanced R&D were developed and several
The first AI industry players with forward-thinking executives started launching pilot collaborations and making small
2013-2015
approaches investments.
● However, only few market players believed in the technology.

● Because AI is still a young approach within the life sciences, many pilot projects failed, creating a lot of
criticism towards the use of deep learning for Drug Discovery and Advanced R&D.
Criticism 2016-2017
● Since then the race for the acquisition of the best, AI startups began.
● Testing of the technology began.

● Capitalization of the industry was continuously growing.

● Many bets of early investors appeared to be justified.
Market cap 2018
growth ● Over the next several years, we can expect to see VC firms and subsidiary funds focused exclusively on
the AI for Drug Discovery subsector, and funds that invest in a maximally-diverse number of AI for Drug
Discovery companies.

Transition ● It is going to be an important milestone in transitioning from the quantity of AI-related collaborations,
from quantity 2019
investments, and M&As to qualitative gains — first practical validations of previously conducted research
to quality
might be appearing during this year.
● Competition for the most successful pharma AI companies will increase drastically.

Intensive 2020-2021
● Pretty much all big players in pharma industry are concerned with AI adoption, the tech has become a
competition
strategic priority, among other things.

Deep Pharma Intelligence 36

Pharma AI Deals

DEEP
PHARMA
INTELLIGENCE
A growing number of collaborations involving AI for drug discovery

Summarizing industry observations over the last five years, we can observe a
fundamental shift in perception of top executives at leading pharmaceutical
organizations about the need of advanced AI technologies. Since 2015, there has
been an obvious shift in the perception from skepticism and cuasious interest, all
the way to a realization of a strategic role AI has to play in the emerging
“data-centric” model of innovation. This change in perception was underpinned by
a number of factors:

- a wave of proof-of-concept studies and research breakthroughs in a wide

range of AI application use cases;
- a number of commercial successes and successfully reached milestones,
involving AI as a central element of research
- substantial advances in democratizing AI technology, where machine
learning and deep learning algorithms become available at scale to
non-AI experts.
- substantial increase in the overall understanding of AI “mechanics”, due The rising interest of leading pharma and
to increasing efforts in the education and professional development with contract research organizations towards
a focus on AI-driven tools and approaches.
AI-driven biotech startups is a major driver for
Pharmaceutical companies of all sizes start competing for AI-expertise, talent, the area to become more attractive for
and partnerships. In this report we summarize some of the most high-profile such investors, since the industry is becoming
collaborations, involving top-20 pharma giants. Even though, we can see a clear
uprising trend in the number of collaborations, focused on AI-drug design, and well-suited for successful exit strategies in
other aspects of data mining and analytics. future.
 Corporation and AI-companies Participating in the Pharma AI Deals

Pharma Partners AI and Biotech Partners

Tech Partners

Deep Pharma Intelligence 39

 Top 10 Leading Corporations by The Number of Major Pharma AI Deals

The leading players by the amount of major

industry partnerships are Bayer, Pfizer and
AstraZeneca.

Implications

These companies demonstrate increasing

commitment to probing the grounds in the AI
space — by investing into internal programs,
as well as partnering with external AI vendors
to pilot programs in drug discovery and other
research areas.

The most common type of deals are true

partnerships and saving the costs deals.

The leading big pharma brands are

increasingly open to partnerships with AI
startups and biotechs to get competitive
edge, and mitigate the problem of declining
R&D efficiency.

Deep Pharma Intelligence 40

 Top AI and Tech Partners by the Number of Pharma AI Deals

Implications

The biggest number of AI in Drug

Discovery deals was conducted by
Exscientia.

The company engages in small molecule

drug discovery, selective single target
molecules, bispecific small molecules,
and phenotypic drug design.

All of the deals concluded with this

company were categorized as the ones
aiming at saving costs and increasing
operational efficiency due to the
character of the services provided.

Deep Pharma Intelligence 41

Top AI Breakthroughs
2018-2020

DEEP
PHARMA
INTELLIGENCE
 Notable AI Breakthroughs
March, 2018

IBM Watson released a cognitive computing platform for Clinical trial matching that has shown significant improvement in patient enrollment rate at
Mayo Clinic. Since its implementation in the Mayo clinic in 2016, the platform demonstrated an 80% increase in enrollment in clinical trials for breast
cancer. The platform also significantly reduced the time to match a clinical trial to one patient.

October, 2018

Healx has prepared a rare disease drug for a Phase 2a clinical trial in 15 months. Healx has demonstrated the power of combining domain expertise,
deep learning, and proprietary data. As a result, the company implemented a scalable platform for drug discovery — Healnet. The drug was created
for the of Fragile X syndrome. It tooks 15 month to conduct lead discovery, preclinical validation, and submitting a publication.

December, 2018

DeepMind built AlphaFold platform to predict 3D protein structure that outperformed all other algorithms. AlphaFold won the CASP13 competition.
AlphaFold was able to most accurately predict the shape for 25 of the 43 proteins from scratch without using previously solved proteins as
templates. AlphaFold uses two methods based on deep neural networks: one is trained to predict the distances between pairs of certain amino
acids, and the other estimates the possible angles of chemical bonds between them.

January, 2019

Recursion Pharmaceuticals has announced progress in its collaboration with Takeda. Recursion has evaluated Takeda’s preclinical and clinical
molecules in over 60 indications in less than 18 month. New drug candidates were identified for 15 indications. Recursion’s AI-enabled drug
discovery platform combines massive biological data generation at scale with state-of-the-art machine learning that can draw meaning from
millions of microscopy images generated in Recursion’s laboratory with Takeda’s compounds.

Deep Pharma Intelligence 43

 Top AI Breakthroughs
September, 2019

1. Insilico Medicine has published a research paper about the first in vivo active drug candidate developed from scratch (de-novo) using GENTRL
system. GENTRL system is a modular drug design platform based on generative adversarial networks (GANs) and other machine learning methods.
A new candidate has been developed staggeringly quickly: in 46 days, including target selection.
2. Deep Genomics created DG12P1 drug using an AI-augmented drug design. It is an antisense oligonucleotide therapy designed via their platform AI
Workbench to treat rare Wilson disease, leading to copper accumulation in the liver, brain and other vital organs. The discovery took under 18 month
from the concept to an actual clinical trials-ready drug candidate, which is way faster compared to classical approaches. Deed Genomics platform
screened over 2,400 diseases and over 100,000 pathogenic mutations. It predicted and confirmed the precise disease-causing mechanism of the
mutation Met645Arg. Then it identified 12 lead candidate molecules.

January, 2020

1. Mendel Recruit proprietary platform could increase patient enrollment for clinical trials by 24-50%. Mendel Recruit platform was applied
retroactively to two completed oncology clinical studies and one that failed to recruit patients at a clinical trial site. Using the Mendel.ai platform
resulted in a 24-50% increase over the standard practice in the number of patients correctly identified as potentially eligible. Mendel applied AI
algorithms that combine the recognition of scanned documents with natural language understanding of clinical records and automated clinical
reasoning.
2. A new drug candidate, DSP-1181, created using Exscientia Centaur Chemist Artificial Intelligence platform began clinical study. The drug was
developed together with Sumitomo Dainippon Pharma for the treatment of obsessive-compulsive disorder, it was advanced to Phase 1 clinical trials.
Less than 12 months was spent to complete the exploratory research phase when it typically takes 4.5 years.

Deep Pharma Intelligence 44

 Top AI Breakthroughs
February, 2020

Scientists from MIT discovered halicin — a new super powerful antibiotic capable to kill 35 the world’s most problematic disease-causing bacteria,
including multiresistant strains. In experiments with E. coli, this bacteria didn’t develop resistance during 30 days. The model applied was able to
screen more than a hundred million chemical compounds in a matter of a day, and is designed to pick out potential antibiotics that kill bacteria using
different mechanisms than those of existing drugs.

September, 2020

1. Aladdin has built a platform for the early diagnostics of Alzheimer’s disease and COVID-19. The company is building biomedical knowledge graphs
— PharmaKG — around age-related disease to reveal mechanisms and potential drugs by uncovering key relationships between disease, genes,
chemical compounds and drugs. Disease Diagnosis platform uses AI and multimodal data, including biomarkers, imaging, blood samples, medical
records, ect.
2. MELLODDY — the ‘Machine Learning Ledger Orchestration for Drug Discovery’ group — was created by ten pharma companies to jointly develop
ML models without sharing data. MELLODDY leverages the world’s largest collection of small molecules with known biochemical or cellular activity
to provide more accurate predictive models and improve drug discovery efficiency. MELLODDY is trying to achieve this by creating a flexible, scalable,
and secure framework for federated and privacy-preserving machine learning that can train and evaluate predictive models related to drug discovery.

Deep Pharma Intelligence 45

Computational
Methods Used by the
Most Advanced AI
Companies

DEEP
PHARMA
INTELLIGENCE
 Computational Methods Used by the Most Advanced AI Companies

Company Computational methods used Technology Abstract

Ardigen is a Polish bioinformatics company, part of the Selvita Group. The

company is active in the field of laboratory information management systems,
biological and clinical data analysis, Big Data integration, as well as custom
Ardigen Bioinformatics, Deep Learning, NLP application development. Through its know-how, experience and products, Ardigen
supports the life science and healthcare industries in executing the idea of
personalized medicine. Ardigen employs world-class specialists in the field of
bioinformatics, biotechnology, mathematics, statistics and computer science.

AtomNet is the first drug discovery algorithm to use a deep convolutional neural
Machine Learning, Deep Learning network. It excels at understanding complex concepts as a combination of
Atomwise (Convolutional neural networks), smaller and smaller pieces of information. AtomNet has been predicting new
cheminformatics potential treatments for two years. It has already explored questions in cancer,
neurological diseases, antivirals, antiparasitics, and antibiotics.

Decodes open- and closed-access data on reagents such as antibodies and

NLP, Deep Learning, Machine
BenchSci present published figures with actionable insights. It allows researchers to: reduce
Learning
time, money, and uncertainty in planning experiments.

Machine Learning, Deep Learning, Evolved from text mining and semantic linking into knowledge graphs. Recent
BenevolentAI
symbolic AI, cheminformatics small efforts into DL and computational chemistry mostly for PR.

Deep Pharma Intelligence 47

 Computational Methods Used by the Most Advanced AI Companies

Company Computational methods used Technology Abstract

Analyze data from patient samples in both healthy and diseased states to
Machine Learning, Deep Learning, generate novel biomarkers and therapeutic targets. Allows researchers to:
Berg
bioinformatics Generate therapeutic targets from biological data in an unbiased way, and
implement personalized medicine at scale.

Automate selection, manipulation, and analysis of cells. Allows researchers to:

Berkeley Lights Machine Learning, bioinformatics Expedite development of cell lines and automate manufacturing of cellular
therapeutics

Process raw phenotypic, imaging, drug, and genomic data sets. Allows
NLP, Deep Learning, Machine researchers to: Integrate rapid analytics and machine learning capabilities into
BioSymetrics
Learning existing business processes to improve care, enhance discoveries, gain insight
into business, and enable fast data-driven decisions.

Bioz has developed a search engine for Life Sciences community using natural
NLP, Deep Learning, Machine language processing and machine learning technology to scan hundreds of
Bioz
Learning millions of pages of complex and unstructured scientific papers on the web. Then
it helps summarize the information into usable visualized format.

Euretos provides direct access to the cloud based discovery platform via user
Machine Learning, Deep Learning, friendly application. It also allows API Integration of the discovery platform in
Euretos
bioinformatics user’s company’s IT environment/workflows, as well as Integration of company
proprietary data and public data in a secure environment.

Deep Pharma Intelligence 48

 Computational Methods Used by the Most Advanced AI Companies

Company Computational methods used Technology Abstract

Machine Learning, Deep Learning, ML for predicting ADME, novelty, synthetic accessibility, pharmacology of
Exscientia
bioinformatics, cheminformatics molecules. Single and multi-target prediction.

Machine Learning, Deep Learning, Iktos has invented and is developing a a technology based on DL for ligand-based
Iktos
cheminformatics de novo drug design, focusing on multi parametric optimization (MPO).

Deep Learning, GANs, GANs +

Reinforcement Learning, symbolic AI, Comprehensive DL pipeline. Biology: Signaling pathways, DNNs for target ID and
Insilico Medicine
Machine Learning, cheminformatics, HTS analysis. Chemistry: GANs-RL for novel molecule generation.
bioinformatics

NLP, Deep Learning, Machine

Kyndi Explainable AI
Learning

Molecular design and analysis. With over 40 years of drug hunting experience
across all major target classes in 6 disease areas both in Lead Generation, Lead
MedChemica Machine Learning, cheminformatics
Optimisation and method development our goal is to accelerate the progress of
our clients programmes.

nferX uses state-of-the-art Neural Networks (shallow and deep learning models)
nference NLP, Deep Learning for real-time, automated extraction of knowledge from the commercial, scientific,
and regulatory body of literature.

Deep Pharma Intelligence 49

 Computational Methods Used by the Most Advanced AI Companies

Company Computational methods used Technology Abstract

Discover connections between drugs and diseases at a systems level by analyzing

Big data analytics; Deep Learning, hundreds of millions of raw human, biological, pharmacological, and clinical data
NuMedii
Machine Learning points. Allows researchers to: find drug candidates and biomarkers predictive of
efficacy for diseases.

Predict the therapeutic potential of food-derived bioactive peptides. Allows

Nuritas Deep Learning, bioinformatics researchers to: cost-effectively develop highly targeted treatments for specific
diseases from natural food sources.

Deep Learning (TensorFlow + Keras World's first protein database specifically for Deep Learning and AI applications
Peptone
base) with full Keras™ and Tensorflow™ integration.

Phenomic predicts which cells will survive chemotherapy and identifies

Deep Learning, Reinforcement compounds that selectively target these resistant cells. It will then develop the
Phenomic AI
Learning compounds and bring them to market. The prediction requires the use of cell
imaging technology, which is where the AI comes in.

ProteinQure is combining quantum computing, reinforcement learning, and

atomistic simulations to design novel protein drugs. Using this mix of
technologies they model essential processes, such as protein folding, and the
Quantum Computing, Reinforcement
ProteinQure underlying physics of interactions between biomolecules. Using their proprietary
Learning, cheminformatics
algorithms and external supercomputing resources, ProteinQure can design small
peptide-based therapeutics (including cyclic peptides), and explore protein
structures without known crystal structures.
Deep Pharma Intelligence 50
 Computational Methods Used by the Most Advanced AI Companies

Company Computational methods used Technology Abstract

CoRE™ is a dynamic and comprehensive in silico predictive modeling platform for

constructing, assessing, validating and deploying exceedingly accurate predictive
Active Learning, Machine Learning, models to efficiently guide the testing process and solve complex drug discovery
Quantitative Medicine
quantum computing optimization problems. CoRE™ applies cutting edge machine learning techniques
from three complementary informatics technologies: Supervised Learning,
Transfer Learning and Active Learning.

Evolutionary algorithms, Machine ML-based structure based predictive models for potency and ADMET/PK
Reverie Labs
Learning properties of small molecules

ReviveMed’s platform for the first time enables the rapid, high-throughput, and
cost-effective application of metabolic data to discover new disease mechanisms
ReviveMed Machine Learning, Deep Learning
for drug discovery and, simultaneously metabolomic biomarkers to identify which
patients stand to benefit by targeting the disease mechanism.

Machine Learning (stochastic

Structura gradient descent and The cryoSPARC System™ enables high-throughput structure discovery of proteins
Biotechnology branch-and-bound maximum and molecular complexes from cryo-EM data with help of machine learning.
likelihood optimization)

XtalPi’s ID4 platform provides accurate predictions on the physiochemical and

XtalPi Quantum physics; Machine Learning pharmaceutical properties of small-molecule candidates for drug design,
solid-form selection, and other critical aspects of drug development.

Deep Pharma Intelligence 51

 Computational Methods Used by the Most Advanced AI Companies

Company Computational methods used Technology Abstract

Bioxcel Corporation is a biopharmaceutical company pioneering the application of

Machine Learning, Deep Learning,
BioXcel artificial intelligence and big data analytics integrated with drug development
cheminformatics
expertise.

C4X innovative DNA-based target identification platform (Taxonomy3(R)) utilises

human genetic datasets to identify novel patient-specific targets leading to greater
discovery productivity and increased probability of clinical success. This is
Machine Learning, Deep Learning,
C4X discovery complemented by C4XD's novel drug design platform which comprises two
cheminformatics, bioinformatics
innovative chemistry technologies, Conformetrix and Molplex, that combine 4D
molecular shape analyses (based on experimental data) with best-in-class
computational chemistry.

CytoReason turns human clinical data into clear biology, to deliver data-driven
Machine Learning, Deep Learning,
target discovery and drug development. CytoReason’s access to unmatched
CytoReason symbolic AI, cheminformatics,
proprietary and public data, combined with cutting-edge machine learning
bioinformatics
technologies, creates their unique biological models of disease, tissue and drug.

Machine Learning, Deep Learning, Deep Genomics is using artificial intelligence to build a new universe of life-saving
Deep Genomics
bioinformatics genetic therapies.

Deep Pharma Intelligence 52

 Computational Methods Used by the Most Advanced AI Companies

Company Computational methods used Technology Abstract

Desktop Genetics is a recognised leader in genome editing technology, staffed by

dedicated team of genome editing experts, bioinformaticians and data scientists,
Desktop Genetics Bioinformatics, Machine Learning driven by the real-world impact of CRISPR technology. Their core technology,
DESKGEN AI, was trained on the largest database of genome editing data in the
world.

C4X innovative DNA-based target identification platform (Taxonomy3(R)) utilises

human genetic datasets to identify novel patient-specific targets leading to greater
discovery productivity and increased probability of clinical success. This is
Machine Learning, Deep Learning,
C4X discovery complemented by C4XD's novel drug design platform which comprises two
cheminformatics, bioinformatics
innovative chemistry technologies, Conformetrix and Molplex, that combine 4D
molecular shape analyses (based on experimental data) with best-in-class
computational chemistry.

The Data4Cure platform's modular architecture allows independent system

components to handle integration and advanced analysis of heterogeneous data
Machine Learning, Deep Learning, types spanning molecular, phenotypic and clinical data, both structured and
Data4Cure
NLP unstructured. Data are mapped to a dynamic biomedical ontology allowing
cross-referencing and joint analyses across thousands of datasets and millions of
publications.

Envisagenics’ SpliceCore platform integrates proprietary machine learning

Machine Learning, Deep Learning,
Envisagenics algorithms, high performance computing, and RNA-splicing analytics to identify
high-performance computing
disease-specific alternatively spliced RNA that will function as therapeutic targets.

Deep Pharma Intelligence 53

 Computational Methods Used by the Most Advanced AI Companies

Company Computational methods used Technology Abstract

Blending computational biology and AI-based methods, Genialis merges and

Genialis Machine Learning, Deep Learning
models data at the intersection of clinical and translational medicine.

GNS Healthcare AI technology integrates and transforms a wide variety of patient

GNS Healthcare Machine Learning, Deep Learning data types into in silico patients which reveal the complex system of interactions
underlying disease progression and drug response.

Healx AI platform uses natural language processing (NLP) to extract disease

knowledge from published sources and to complement biomedical databases and
Machine Learning, NLP, symbolic AI, proprietary, curated data. The data is integrated in the form of the largest, rare
Healx
cheminformatics, bioinformatics disease-focused Knowledge Graph. It shows prioritised hidden and novel
connections between drugs and diseases when explored by expert
pharmacologists and biologists.

Deep Pharma Intelligence 54

20 Notable R&D Use
Cases of AI
Application in
Biopharma

DEEP
PHARMA
INTELLIGENCE
 Introduction to Most Innovative R&D Approaches of AI in Biopharma
The industry of AI in Biopharma continues to grow after a long period of skepsis, which is reflected in ongoing flow of investments and increase in the
number of collaborations between pharmaceutical corporations and AI companies in 2020 compared to 2019 and previous years. The difference
between Pharma and Biopharma fields is that biopharma medicines and drug products are manufactured in living organisms like bacteria, yeast and
mammalian cells. The prefix “bio” refers to how drugs are produced. Biopharma is the subset of drugs produced by biological methods.
Pharmaceutical drugs cover biological means as well as chemical synthesis.
The Biopharma industry’s growth dynamics is largely influenced by the more active participation of largest pharmaceutical corporations in the
AI-related investment and research collaborations. Despite some Pharma corporations still being critical about AI applications, the volume of
research, number of scientific publications in the field of AI in Biopharma, and research collaborations between pharma companies and AI-expertise
vendors are rapidly increasing.
Research in AI is facing challenges today, but the demand for the ML/AI technologies, as well as for ML/AI talent, is growing in pharmaceutical and
healthcare industries and driving the formation of a new interdisciplinary field — data-driven drug discovery/healthcare. The overall success of all the
companies in the industry depends strongly on the presence of highly skilled interdisciplinary leaders. It will be crucial to hire top AI experts, especially
for Big Pharma companies that are fighting to survive.
Trending and most innovative R&D approaches of top AI in Biopharma companies include application of:

Cognitive
Deep Natural Language
Machine Learning Reasoning
Learning Processing
Technologies

Deep Pharma Intelligence 56

 Most Innovative R&D Approaches of AI in Biopharma. Abbvie
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. The company's
mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that
address some of the world's most complex and serious diseases.
There is not much information about use of artificial intelligence in drug discovery by AbbVie. But it does have a confidential project listed with
Atomwise. Also, in September 2016, together with its partner AiCure, AbbVie announced how its AI-based patient monitoring platform improved
adherence in an AbbVie phase 2 schizophrenia trial.
Main focus areas: The way AI is used:
● to visually confirm medication ingestion;
● to increase medication adherence in patients;

Alzheimer’s ● to use data to assess effectiveness of treatment.

Disease Cooperation:
● AiCure
Schizophrenia ● Mission Therapeutics

Parkinson's
Disease

Source Crunchbase

Deep Pharma Intelligence 57

 How Abbvie Uses AI in R&D?
Abbvie and Mission Therapeutics collaboration is aimed at developing DUB inhibitors that promise to treat two currently incurable
conditions, Parkinson’s and Alzheimer’s diseases. With over 50 million Americans struggling Alzheimer’s and dementia, this AI
partnership will bring treatment closer and hope for many.
1. Abbvie in cooperation with another AI-specialized company AiCure, a clinically-validated artificial intelligence company that visually confirms
medication ingestion on smartphones, announced that study results presented during the International Society for CNS Clinical Trials and
Methodology (ISCTM) Scientific Sessions confirm that use of the AiCure Platform significantly increases medication adherence in patients with
schizophrenia, as measured by drug concentration levels.
Subjects were monitored Adherence was measured
Subjects were dosed once
Subjects of the investigation either by AiCure or by by review of returned
daily (QD) 25, 50, or 75mg
were enrolled and modified Directly study drug blister and
ABT-126 or matching
randomized to placebo or Observed Therapy scheduled
placebo, as 3 capsules in
ABT-126 (mDOT) at least 3 times pharmacokinetic
the morning for 24 weeks
per week sampling

2. The sub-study was part of a larger Phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, parallel-group, study in
nonsmoking subjects with schizophrenia who were clinically stable. Subjects were enrolled and randomized to placebo or ABT-126. The AiCure
platform was introduced in 10 of 31 US sites; subjects were monitored either by AiCure or by modified Directly Observed Therapy (mDOT) at
least 3 times per week. In addition, adherence was measured by review of returned study drug blister and scheduled pharmacokinetic sampling.
3. Results: cumulative adherence, measured by study drug concentrations above the LLOQ (minimum required therapeutic level), were higher
through 24 weeks for subjects monitored using the AiCure platform (89.7%) compared with subjects monitored using mDOT (71.9%). This
research adds to the growing body of scientific evidence showing the advantages of using AI to increase statistical power and reduce sample
size in clinical trials, thereby decreasing costs and accelerating drug development.

Source AiCure Blog.Benchsci Healthcare Weekly

Deep Pharma Intelligence 58

 Most Innovative R&D Approaches of AI in Biopharma. AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company, whose innovative medicines are used by millions of patients
worldwide. Jim Weatherall, Vice President in AstraZeneca, said that data science and AI has the potential to transform the way they
develop new medicines – turning yesterday’s science fiction into today’s reality with the aim of enabling the translation of innovative
science into life-changing medicines.
AstraZeneca uses AI to combine information from multiple sources in order to draw more accurate conclusions than if science literature was
analysed by hand. AI also has the potential to find patterns in these graphs revealing previously unexplored hypotheses.
Main focus areas: The way AI is used:
● to build disease understanding through
knowledge graphs to integrate genomic, disease,
drug and safety information;
● to identify new targets for novel medicines;
Kidney Disease
● for fast, accurate image analysis.
Cooperation:
Fibrosis ● Schrödinger

Source AstraZeneca

Deep Pharma Intelligence 59

 How AstraZeneca Uses AI in R&D?
AstraZeneca focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of
diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The company has turned to AI to cut
development costs by improving the efficiency of repetitive tasks and engendering better-informed decision.
1. The knowledge graphs are used to give scientists the information they need about genes, proteins, diseases and compounds and how they
relate to each other. Using AI to combine information from multiple sources, they hope to draw more accurate conclusions than if researchers
analysed science literature by hand. AI also has the potential to find patterns in these graphs revealing previously unexplored hypotheses. The
company's knowledge graphs integrate:

Genomic Disease Drug Safety

Researchers can ask key questions to help identify and prioritise drug targets

2. Discovering a potential drug molecule requires several years of detailed scientific research. AI is enabling us to rapidly generate novel ideas for
molecules to make and rank these ideas using predictions based on large data sets available to us. Having identified promising molecules, the
next step is to synthesise the molecules in the laboratory. AI is starting to help here too – the science of synthesis prediction is rapidly evolving
and scientist will soon be able to use AI to help deduce the best way to make a molecule in the shortest time.
3. AI systems are trained to assist pathologists in analysing samples accurately and more effortlessly. This has the potential to cut analysis time
by over 30%. For one of their AI systems, they implemented an approach inspired from how some self-driving cars understand their
environment. They trained the AI system to score tumour cells and immune cells for a biomarker, called PD-L1, which has potential to help
inform immunotherapy-based treatment decisions for bladder cancer.

Source AstraZeneca TechCrunch

Deep Pharma Intelligence 60

 Most Innovative R&D Approaches of AI in Biopharma. Amgen
Amgen is one of the world’s leading biotechnology companies committed to unlocking the potential of biology for patients suffering
from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins
by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human
biology.
AI is but one of a series of emerging digital capabilities Amgen is advancing to improve how they do a whole host of activities across the company —
from drug discovery and patient identification to optimized interactions with physicians. Other technologies that company is leveraging include digital
automation, natural language processing, advanced analytics.
Main focus areas: The way AI is used:
● to boost the accuracy of risk predictions;
● to provide personalized approach to patient care;
Cardiovascular ● to support compliance via real-time answers with
Diseases accuracy, consistency;
● to use data to determine the most effective
Osteoporosis
treatment.
Cooperation:
● Owkin

Source Wired

Deep Pharma Intelligence 61

 How Amgen Uses AI in R&D?
Amgen is piloting a process using AI that has the potential to greatly enhance its ability to find patterns in manufacturing deviations
and to prevent their recurrence. The AI tool will replace a manual, labor-intensive process with one that can look across large data sets
and find correlations between obscure signals and events which the previous system could have missed.
1. While large company manufactures, purifies, and packages biotech drugs, a huge amount of diverse data is generated, not all of which is
digitized. The focus of Amgen is the application of data science specifically in quality operations, using a data science process:

Quality data sciences creates solutions that unlock

and leverage data. These solutions will efficiently
Ask an Explore the provide insights and intelligence for the Quality
Get the data Model the data Visualise the
interesting data Operation. This involves:
results
question
1) Ensuring data access; 2) Application of
appropriate analysis methods to unlock
information; 3) Meaningful visualisation

2. Amgen have created a project team to look for a system algorithm that could replicate and perhaps improve upon the manual process. The goal
was to think big but start small and build a product that could be deployed across the manufacturing network. Using an agile development
approach and natural language processing (NLP) tools, the team developed a consistent algorithm that was able to reasonably replicate the
manual process.
NLP is described as an AI technology that turns text into numbers, which can be read by a computer and used to identify similar records. Each
record has a series of numbers associated with it that can be analyzed to create similarity scores. The records can then be clustered together.
Those clusters can then be given to an subject matter expert, who can decide if there is trending and if action should be taken. Feedback can
then be given to the algorithm, which can be adjusted.

Source Wired Pharmaceutical Online

Deep Pharma Intelligence 62

 Most Innovative R&D Approaches of AI in Biopharma. BenevolentAI
BenevolentAI is the global leader in the application of AI for scientific innovation. The company's aim is to accelerate the journey from
inventive ideas to medicines for patients by developing AI to generate new treatments for some of the world’s 8,000 untreated
diseases. BenevolentAI integrates AI technologies at every step of the drug discovery process: from early discovery to late stage
clinical development.
The company has developed the Benevolent Platform™ — a leading computational and experimental discovery platform that allows our scientists to
find new ways to treat disease and personalise medicines to patients. The Benevolent Platform™ focuses on three key areas: Target Identification,
Molecular Design and Precision Medicine.
The way AI is used:
Main focus areas: ● to force the discovery of drug patterns;
● to collect more diverse data;
● to identificate specific target;
Kidney Disease
● in molecular design;
● in patient stratification.
Cancer Cooperation:
Fibrosis
● Neuropore Therapies
● Novartis
Parkinson's
Disease

Source Wired Benevolent.ai

Deep Pharma Intelligence 63

 How BenevolentAI Uses AI in R&D?
The Benevolent Platform™ of computational and experimental technologies and processes draws on vast quantities of mined and
inferred biomedical data and is built and used by their world-class scientists, researchers, and technologists, working side-by-side, to
improve and accelerate every steps of the drug discovery process.
1. BenevolentAI uses AI to mine and analyse biomedical information, from clinical trials data to academic papers. The company's approach:

2. BenevolentAI has spent the last five years developing a knowledge

pipeline that pulls data from various structured and unstructured
AI-Augmented
molecular design biomedical data sources and curates and standardizes this
Hypothesis Patient knowledge via a data fabric.
generation and stratification for
target better clinical This is fed into our proprietary knowledge graph which extracts and
identification Benevolent
trials contextualises the relevant information.
Knowledge Graph
including The knowledge graph is made up of a vast number of
algorithmically
derived knowledge
contextualised, machine curated relationships between diseases,
genes, drugs and with over 20 types of biomedical entities.
AI
3. Relation inference AI models help to predict potential non-obvious disease targets that may be overlooked. Their specific expression based
models help to identify proteins, genes that express differently in a disease and healthy cell.
4. By leveraging advanced AI, the EvoChem product designs de novo compounds based on multiparametric optimisations with a scoring function
that factors in all the properties the company is seeking to optimise for that molecule.
5. Company applies ML models to identify patient groups by the molecular signature of their disease and design, allowing to run faster clinical
trials.
Source Wired Benevolent.ai

Deep Pharma Intelligence 64

 Most Innovative R&D Approaches of AI in Biopharma. Boehringer Ingelheim
Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one. The company's key areas of
interest are: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system.
The focus of the company’s AI-related activity is in doing so is on diseases for which no satisfactory treatment option exists to date. The company
therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced
prevention.
The way AI is used:
Main focus areas: ● to boost the efficiency speed;
● to reduce the time needed to discover a new drug;
● to improve the quality of discovered drugs and
molecules.
Cooperation:
Alzheimer’s
Disease ● Bactevo
● Bi X
ALS
Schizophrenia

Parkinson's
Disease

Source Boehringer

Deep Pharma Intelligence 65

 How Boehringer Ingelheim Uses AI in R&D?
Boehringer Ingelheim has partnered with UK-based AI tech company Bactevo to speed up its drug discovery efforts. In this
collaboration, Boehringer will leverage Bactevo’s AI-powered platform – Totally Integrated Medicines Engine platform (TIME) – to
boost the efficiency, speed, and quality of drug discovery from small molecule lead compounds. As a result they obtain the reduction
of time to take drugs to market for treatment of conditions caused by defects in mitochondrial function. It essentially brings together
the powerful drug research experience at Boehringer and state of the art TIME drug discovery platform to discover new medicines for
ALS, Parkinson’s disease and Alzheimer’s disease.
1. With the founding of BI X as independent subsidiary Boehringer Ingelheim will focus on breakthrough innovative digital solutions in healthcare
from idea to pilot. The start-up will work closely together with all three business units of the company - Human Pharma, Animal Health and
Biopharmaceuticals. It will provide a platform for collaborating with specialists in the field of data science, agile software development and user
experience design.
2. BI X will develop prototypes for new products and solutions and test them together with the company's business units in pilot phases. The
business units will then use the successfully developed new products and solutions themselves and bring them to the market. This approach is
to ensure that knowledge and experience accrued at BI X are being quickly integrated into the digital lab's parent house.
3. Analytical algorithms in audio tools can lead to advances in the earlier diagnosis of diseases in humans and animals. SoundTalks, an audio
monitoring system for the early detection of respiratory diseases, is currently being tested in livestock farming. In humans as well, faster
treatment can slow or even halt the progression of a disease – which is essential, particularly for central nervous system disorders. Intelligent
speech recognition software – via smartphone, for example – will be able to analyze speech patterns, recognize risks, and thereby contribute to
a reliable diagnosis and effective therapy.

Source eHealth News pmlive

Deep Pharma Intelligence 66

 Most Innovative R&D Approaches of AI in Biopharma. Celgene
Their vision as a company is to build a major biopharmaceutical corporation while focusing on the discovery, the development, and the
commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than
300 clinical trials at medical centers using compounds from Celgene. The company is transforming pharmacovigilance (PV) to drive
the new era of patient safety.
Pharmacovigilance detects, assesses, and prevents adverse events (AEs) and other drug-related problems by collecting, evaluating, and acting upon
AEs. The value of using AI methodologies in PV is compelling; however, as PV is highly regulated, acceptability will require assurances of quality,
consistency, and standardization.
Main focus areas: The way AI is used:
● to speed up the discovery of drug candidates for
for cancer and autoimmune diseases;

Autoimmunity
● to identify and standardize PV knowledge
elements;
● to develop, review and validate cognitive services;
Cancer ● to increase operational efficiency, consistency,
quality of data collection, and signal detection.
Cooperation:
Pharmacovigilance
● GNS Healthcare

Source Springer

Deep Pharma Intelligence 67

 How Celgene Uses AI in R&D?
Celgene force boost AI implementation in drug discovery particularly machine learning and deep learning. Machine learning involves
computing techniques that analyze vast amounts of data to find understanding that might be too abstract and time consuming for
humans. Deep learning takes that even further, using code that attempts to mimic the brain’s ability to recognize patterns in
unstructured data.
1. In the past, researchers relied on imperfect image-processing algorithms to analyze cancer cells, and then they corrected them by hand. With
tens of thousands of cells, this required a huge expenditure of time and effort. But using deep learning, images can be processed almost
instantaneously with much better results. For these analyses use:
Amazon SageMaker
machine-learning
platform
Virtually analyzing the
Toxicology *without putting live patients
biological impact of a
potential drug prediction (or even lab rats) at risk
Apache MXNet
deep-learning
framework
2. Pharmaceutical research revolves heavily around exceedingly complex algorithms to predict how certain compounds will interact with the
human body. To this end, Celgene uses high-performance Amazon EC2 P3 instances powered by NVIDIA Tesla V100 Tensor Core GPUs
(graphics processing units) to process the complexity. These NVIDIA GPUs have thousands of cores that accelerate the training of
machine-learning models (which can, for instance, test the effectiveness of a drug at faster and more accurate rates). The results have been
game changing: A model that once took two months to train can now be trained in four hours.
3. AI is used to identify areas across the pharmacovigilance (PV) value chain that can be augmented by cognitive service solutions using the
methodologies of contextual analysis and cognitive load theory. It will also provide a framework of how to validate these PV cognitive services
leveraging the acceptable quality limit approach.

Source Springer Labiotech AWS Amazon

Deep Pharma Intelligence 68

 Most Innovative R&D Approaches of AI in Biopharma. GSK
GlaxoSmithKline has 3 global businesses - Pharmaceuticals, Vaccines, Consumer Healthcare - that research, develop and
manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. Their R&D approach focuses on
science related to the immune system, use of genetics and advanced technologies.
GlaxoSmithKline has many deals with different companies such as Exscientia, Insilico Medicine, Insilico Biotechnology to use new computer
modelling systems to bring differentiated, high-quality and needed healthcare products.
Main focus areas: The way AI is used:
● to improve the discovery of drugs, biomarkers,
and new vaccines;
● to interpret and understand genetics and
genomic data;
Vaccines ● to understand the effect of interventions on
diseases.
Cooperation:
Immune System
● Exscientia
● Insilico Medicine

Biomarkers

Source GSK

Deep Pharma Intelligence 69

 How GSK Uses AI in R&D?
The goal of GSK is to achieve a sustainable flow of meaningful new treatments, utilising modalities such as small molecules,
antibodies, antibody drug conjugates and cells, either alone or in combination. Their research focuses on science related to the
immune system and human genetics, while leveraging advanced technologies including functional genomics, AI and machine
learning.
1. According to the GSK and Exscientia collaboration, AI enabled platform will be applied and combined with the expertise of GSK, in order to
discover novel and selective small molecules for up to 10 disease-related targets, nominated by GSK across multiple therapeutic areas.
2. GSK evaluates Insilico Medicine technology in the identification of novel biological targets and pathways of interest to GSK to enhance its drug
discovery process.
3. GSK uses Insilico' Biotechnology technology platform to analyse predictive simulations of cell responses. As a result an almost unlimited
number of scenarios will be generated and utilized to significantly reduce the number of experiments necessary during bioprocess
development. This has the potential to cut down the time taken to research Vaccine manufacturing processes and could therefore speed up the
time-to-market for candidate Vaccines in GSK's research portfolio.
Insilico's technology is built around Insilico Cells™:

Genome-based Models become

Simulation of cells
mechanistic network Models are refined and individualized
behavior in a
models of common host calibrated representation of the
bioprocess
organisms specific cells in silico

Source GSK Eurekalert Insilico Biotechnology

Deep Pharma Intelligence 70

 Most Innovative R&D Approaches of AI in Biopharma. Gilead
Gilead is focused on developing and delivering medications that advance the treatment of life-threatening diseases. The commercial
success of their products provides them with the resources to generate new clinical data defining their profiles and supports their
development of new therapeutic advancements. As they bring new products into clinical development, their goal remains the same –
to discover, develop and commercialize therapeutics that advance patient care.
In spring 2019 Gilead and insitro announced that the companies have entered into a strategic collaboration to discover and develop therapies for
patients with nonalcoholic steatohepatitis (NASH).
Main focus areas: The way AI is used:
● to сreate disease model;
● to discover new targets that influence disease
progression and regression.

Cooperation:
● insitro
Nonalcoholic
Steatohepatitis

Source Gilead

Deep Pharma Intelligence 71

 How Gilead Uses AI in R&D?
According to John McHutchison, the company’s Head of Research and Development, Gilead is committed to researching and
developing treatments for patients living with NASH, particularly those with advanced fibrosis who have the greatest unmet need.
Gilead is able to utilize deep learning to explore the scientific underpinnings of the biology and clinical spectrum of NASH, with the
goal of accelerating the development of highly effective treatment options for patients with this disease.
1. The startup's insitro Human platform combines AI with human genetics and genomic data to provide insights into the disease's makeup and
progression, propose forms of treatment and predict patient responses to those therapies. With that information, Gilead is planning to
chemically develop up to five of the proposed treatments for NASH.
2. By generating high-throughput, functional genomic data sets that align with patient data, and interpreting those data via novel machine learning
methods, insitro builds predictive models that can accelerate target selection and the design of effective therapeutics. The company is building
a high-throughput bio-data factory based on state-of-the-art technologies from bioengineering, allowing the creation of large data sets that
enable cutting edge machine learning methods to be brought to bear on key bottlenecks in drug development.
Target 1
Gilead datasets Target 2
Insitro IHS Data interpretation Design of new
from patients with machine Predictive model
platform
Target 3 drugs &
and preclinical learning methods
Target 4 therapeutics
trials
Target 5

3. The insitro Human (ISH) platform applies machine learning, human genetics and functional genomics to generate and optimize unique in vitro
models and drive therapeutic discovery and development. The ISH platform provides insights into disease progression, suggest candidate
targets, and predict patient responses to potential therapeutic interventions. Gilead can advance up to five targets identified through this
collaboration and is responsible for chemistry and development against these targets.

Source Wire GEN Beckershospitalreview

Deep Pharma Intelligence 72

 Most Innovative R&D Approaches of AI in Biopharma. Insilico Medicine
Insilico Medicine, Inc. is a bioinformatics company located at the Emerging Technology Centers at the Johns Hopkins University
Eastern campus in Baltimore. It utilizes advances in genomics, big data analysis and deep learning for in silico drug discovery and
drug repurposing for age-related diseases. The company pursues internal drug discovery programs and geroprotector discovery and
provides services to pharmaceutical companies.
Combining genomics, big data analysis, and deep learning, the company has been using artificial intelligence algorithms to potentially discover the
next world-changing drug.
Main focus areas: The way AI is used:
● to cheaper and faster discover of drug molecules;
● to imagine new molecules with drug-like
properties;
Alzheimer’s
Disease
● to find new drug candidates, biological targets
and molecules;
● to validate the targets, using novel chemistry.
Sarcopenia
Cancer Cooperation:
● BioTime
Parkinson's ● Juvenescence AI Limited
Disease
● Bitfury

Fibrosis

Source Eurekalert Insilico

Deep Pharma Intelligence 73

 How Insilico Medicine Uses AI in R&D?
Next-generation AI developed by Insilico Medicine can be used to validate, assess and improve the quality of biological samples as
well as learn using large volumes of heterogeneous data without human intervention. Multiple new methodologies including the
feature importance, deep feature selection and deep pathway analysis among the others can provide the biologically-relevant
interpretation of the inner workings of the AI systems.
1. Since 2016, Insilico Medicine researchers have been working to get GANs (Generative Adversarial Networks consisting of two distinct neural
networks) to “imagine” new molecules with drug-like properties. In 2017, they combined this with another type of groundbreaking A.I. in the form
of Reinforcement Learning. Reinforcement Learning is built around the notion of A.I. agents which use trial-and-error to maximize some kind of
reward.

Nominated Rapid in vitro in vivo Pre-clinical

GENR
Target synthesis assays assays Trials

2. Insilico Medicine has developed GENTRL (Generative Tensorial Reinforcement Learning), a new artificial intelligence system for drug discovery
that dramatically accelerates the process from years to days (from 3 years to 21 days before first synthesis and trials). In the industry’s first
successful experimental validation of such AI technology for drug discovery in cells and animals, Insilico successfully tested the technology by
creating a series of entirely new molecules capable of combating disorders like fibrosis.
3. The system bucks the standard brute-force approach for AI drug development, which involves screening millions of potential molecular
structures looking for a viable fit, in favor of a creative AI algorithm that can imagine potential protein structures based on existing research and
certain preprogrammed design criteria. Insilico's system initially produced 30,000 possible designs, which the research team whittled down to
six that were synthesized in the lab, with one design eventually tested on mice to promising results.

Source Biospace Digital Trends Business Insider

Deep Pharma Intelligence 74

 Most Innovative R&D Approaches of AI in Biopharma. Nuritas
Nuritas is revolutionising the discovery of novel, natural and scientifically proven active ingredients that can manage and improve
human health. The company’s disruptive computational approach to discovery uses artificial intelligence and genomics to, for the first
time ever, rapidly and efficiently predict and then provide access to the most health-benefiting components hidden within food, called
bioactive peptides.
Their bioactive peptides provide patented innovative solutions to companies needing new therapeutic options to deal with significant unmet medical
needs. The Bioactive Peptides they discover have the potential to offer new and innovative treatments for many of the illnesses that are becoming
more prevalent as the world population continues to expand and age.
Main focus areas: The way AI is used:
● to target, predict and unlock novel bioactive
peptides;

Inflammation
● to deliver highly specific, efficient and
life-changing health solutions;
Cooperation:
Skin Diseases ● BASF

Source Nuritas

Deep Pharma Intelligence 75

 How Nuritas Uses AI in R&D?
At Nuritas, they recognise the vast untapped potential that exists in naturally occurring Bioactive Peptides. Their unique discovery
platform targets, predicts and unlocks these natural ingredients to provide new solutions and opportunities for their partners across a
wide range of application areas. Together with their partners, they are changing the lives of billions of people worldwide.
1. They begin the discovery process by precisely defining the health condition and targets they wish to modulate. They then use proprietary search
tools to identify the characteristics specific to their area of focus. The most up-to-date academic and scientific knowledge is used to maximise
the efficiency and effectiveness of prediction algorithms.

Naturally Sourced High Speed

Ingredients Prediction
Identifying the Predicting the
key bioactive peptides’ Unlocking Sustainability
Defining of
characteristics effect using deep peptides from
targets to BENEFITS
of the focus learning algorithms food source Targeted
modulate
area Approach
Cost Effective Product
Innovation Differentiation
2. Having begun the discovery process as above, Nuritas takes advantage of multiple proprietary AI algorithms, including deep learning. Using
these, they are now uniquely able to predict which novel food-derived bioactive peptides deliver the pre-determined effect that they are seeking.
This cuts out many thousands of hours of trial and error.
3. After targeting and predicting high potential Bioactive Peptides, Nuritas unlocks them from within the food source for their pre-defined
therapeutic use.
4. Their library of plant and animal derived Bioactive Peptides have gone through hundreds of millions of years of selective evolution to become
the most potent repairers, healers and protectors.
Source Nuritas

Deep Pharma Intelligence 76

 Most Innovative R&D Approaches of AI in Biopharma. Novo Nordisk
Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has
given us experience and capabilities that also enable us to help people defeat other serious chronic diseases: haemophilia, growth
disorders and obesity. At Novo Nordisk, they are driving change to defeat diabetes and other serious chronic diseases.
Novo Nordisk cooperates with e-Therapeutics to use its AI-based drug discovery technology to find new therapies for type 2 diabetes. e-Therapeutics
uses a suite of powerful computational tools to augment and interrogate the vast amount of biological information currently available in both public
and private databases.
Main focus areas: The way AI is used:
● to identify novel intervention strategies;
● to find new biological pathways and compounds;
● tease out previously unknown disease processes
and pathways;
● to form the basis for new therapies.
Cooperation:
Type 2 Diabetes
● e-Therapeutics

Source Pharma Forum

Deep Pharma Intelligence 77

 How Novo Nordisk Uses AI in R&D?
The company said this approach more realistically reflects the true complexity of disease with its multiple and often interconnected
cellular pathways. Novo Nordisk already has a research centre in Oxford, where visiting researchers are working with Oxford University
academics to advance development of therapies for type 2 diabetes.
1. Using techniques such as machine learning and state of the art data analysis, e-Therapeutics creates and analyses network models of disease
to identify likely proteins that could be disrupted to treat diseases. Company’s scientists use AI to improve and accelerate active pharmaceutical
ingredient (API) and drug product (DP) designs of new peptides and biologics. They have access to advanced state-of-the-art protein modelling
software and are applying data science tools and prediction models to a variety of biological and chemical data, including high-throughput
analytical data and images.
AI-related research department structure
Modelling scientists Data scientists Data engineers

Modelling of molecules and proteins Ensuring that entire working

Understanding and applying of
in order to create better and more infrastructure is as agile and stable
complex machine learning algorithms
stable drugs as possible

2. Novo Nordisk is the first pharma partner to sign up to use the GAIN platform, which taps into genome-wide association study (GWAS) data to
find mutations in DNA linked to disease traits and – according to the UK company – bridges the gap between genetic susceptibility and disease
mechanism. While many gene variants discovered using GWAS studies often don’t map to a plausible biological mechanism, e-Therapeutics
says its “network biology” approach can improve the hit rate.
3. Using GAINs, the company will be able to interrogate genomics data from patients with complex, polygenic disease and shed new light on
important and novel biological pathways for particular groups of patients.

Source Novo Nordisk Pharma Forum

Deep Pharma Intelligence 78

 Most Innovative R&D Approaches of AI in Biopharma. Pfizer
Pfizer is a leading research-based biopharmaceutical company. They apply science and their global resources to deliver innovative
therapies that extend and significantly improve lives. The company's products are the results of 1500 scientists overseeing more than
500,000 lab tests and over 36 clinical trials before the first prescription.
Pfizer in late 2016 announced a collaboration that will utilize IBM Watson for Drug Discovery. Pfizer is using IBM’s AI technology on its
immuno-oncology research, a strategy of using a body’s immune system to help fight cancer. Based on their research, this appears to be one of the
first significant uses of Watson for drug discovery.
Main focus areas: The way AI is used:
● to uncover new information or insights related to
patient needs;
● to analyze massive volumes of disparate data
Hematologic sources, including licensed and publicly available
Malignancies
data;
● to discover new drug targets and alternative drug
Cancer indications.
Cooperation:
● IBM Watson
Menopause

Source Pfizer

Deep Pharma Intelligence 79

 How Pfizer Uses AI in R&D?
Pfizer is among the healthcare companies investing heavily in AI and teamed with IBM Watson to identify better targets for cancer
during the discovery phase and Concerto HealthAI to to apply real-world datasets and artificial intelligence techniques to develop new
and more precise treatment options for patients with solid tumors and hematologic malignancies.
1. Pfizer is one of the first organizations worldwide to deploy Watson for Drug Discovery, and the first to customize the cloud-based cognitive tool:

Cognitive
Natural language
Machine learning reasoning
processing
technologies

Supporting the identification of new drug targets, combination therapies for study, and patient selection
strategies in immuno-oncology

2. Pfizer uses newly launched Watson for Drug Discovery, a cloud-based offering that aims to help life sciences researchers discover new drug
targets and alternative drug indications. The average researcher reads between 200 and 300 articles in a given year 2, while Watson for Drug
Discovery has ingested 25 million Medline abstracts, more than 1 million full-text medical journal articles, 4 million patents and is regularly
updated. Watson for Drug Discovery can be augmented with an organization's private data such as lab reports and can help researchers look
across disparate data sets to surface relationships and reveal hidden patterns through dynamic visualizations.
3. AI systems are used in progressive ways to analyze data, to uncover new information or insights related to patient needs.

Source Pfizer Medtechdive Pfizer

Deep Pharma Intelligence 80

 Most Innovative R&D Approaches of AI in Biopharma. Roche
To intensify it`s on healthcare, Roche divests two businesses: fragrances and flavours, and vitamins and fine chemicals. As a
research-driven company committed to innovation, the Group’s Pharmaceuticals and Diagnostics Divisions supply products spanning
the healthcare spectrum, from the early detection and prevention of disease to diagnosis and treatment.
Sensors, wearables, IOT, blockchain, high performance compute, Machine Learning and Deep Learning are drivers and enables of digital
transformation of Roche`s entire Pharma value chain. AI is expected to have a dramatic impact on medicine that Roche provides.
Main focus areas: The way AI is used:
● to improve the ability to diagnose disease;
● to select the best treatments for individual
patients;
● to De novo compound design;
Asthma ● to better target selection.
Cooperation:
Diabetic Macular ● Owkin
Edema
Cancer

Diabetes

Neurodegenerative
Diseases

Source Roche

Deep Pharma Intelligence 81

 How Roche Uses AI in R&D?
With the advent of more sophisticated digital technologies, personalised healthcare is entering a new phase, expanding from
companion diagnostics to a more complex, holistic view of patient health generated from a wide variety of data sources. Combining
and standardising data, using AI and algorithms to make sense of it all, enhance the way Roche can develop and bring medicines to
patients in a much more targeted fashion.
1. Examples of transformative digital use cases across different areas, modalities and pipeline phases:

Machine Learning Deep Learning AI and Wearables

Molecule discovery Deep image analysis in Digital biomarkers

and optimization Ophthalmology in Neuroscience

2. AI could revolutionise the way ophthalmologists diagnose diabetic macular edema (DME), a complication of diabetes that causes a thickening
of the retina that can lead to irreversible blindness if left untreated. The best way to prevent DME is through regular eye exams that use a
technique called colour fundus photography (CFP) and optical coherence tomography (OCT). The company's researchers use deep learning to
teach computers how to estimate macular thickness from CFP images, making DME diagnosis easier, so they gave their computers a large set
of CFP and OCT data from participants in two large DME clinical trials to train on.
The deep learning system examined a total of 17,997 CFP images from ~700 patients and compared them with corresponding OCT thickness
measurements. Deep learning could even do a reliable job of predicting the actual OCT measurement of the macula’s thickness from a CFP
image if it was of sufficient quality.

Source Roche Roche

Deep Pharma Intelligence 82

 Most Innovative R&D Approaches of AI in Biopharma. Sanofi
Sanofi is a healthcare company engaged in the research, development, manufacturing, and marketing of innovative therapeutic
solutions. It covers areas such as diabetes solutions, human vaccines, innovative drugs, consumer healthcare, etc. Its products
includes prescriptions and over-the-counter drugs for thrombosis, cardiovascular disease, diabetes, central nervous system disorders,
oncology and internal medicine, vaccines.
Sanofi and Google apply artificial intelligence (AI) across diverse datasets to better forecast sales and inform marketing and supply chain efforts.
Using AI will take into account real-time information as well as geographic, logistic and manufacturing constraints to help the accuracy of these
complex activities.
The way AI is used:
Main focus areas: ● to provide remote connection between patients
and doctors;
● to diagnose diseases at early stage;
Diabetes ● to decentralize clinical trials;
● to improve marketing strategies.

Cancer Cooperation:
Pneumonia
● Google

Central Nervous
System

Heart Diseases

Source Crunchbase

Deep Pharma Intelligence 83

 How Sanofi Uses AI in R&D?
Big data and a better understanding of the human genome are also providing medical professionals with better tools to make faster,
more accurate diagnoses and deliver more personalized treatments. Large, multinational databases of clinical data called patient
registries can also play a key role in the study of rare diseases. Additionally, Sanofi IT will be modernizing its infrastructure by
migrating some existing business applications to Google Cloud Platform (GCP).

Mouthlab

1. MouthLab is a single, noninvasive device that measures more than 10 different health indicators in less than a minute. The AI-powered system
uses the patient’s mouth and hand to measure in real-time vital health signs typically monitored at the doctor’s office, including respiratory rate,
pulse, electrocardiogram, blood oxygen saturation, temperature, blood pressure, and several lung functions. In addition, the device connects to
the cloud, so patient data is accessible in real time to physicians and caregivers. By making this data easily available, Sanofi aims to reduce
hospitalizations, patient costs and risks.
Wavy Assistant

2. Wavy Assistant delivers continuous real-time heart health monitoring using voice and AI solutions. After a patient’s data is collected and
analyzed, Wavy can provide advice tailored to that individual. Our heart health monitoring solution uses a smart home speaker as its main user
interface, which allows customers to interact with their heart health easily through a natural conversation instead of a mobile app. If the system
detects something is wrong, Wavy instantly sends an emergency signal to designated doctors, friends and family. It can also trigger an
immediate alert during emergency situations. Almost all heart attacks and strokes happen at home and most of the damage occurs because
the emergency services are called too late.
LIFEdata
3. LIFEdata is an intuitive, easy to use AI platform that automates personally tailored conversational experiences across all channels. In terms of
user experience, healthcare is no different than any other industry.

Source Sanofi

Deep Pharma Intelligence 84

 How Sanofi Uses AI in R&D?

ChatbotPack.com

4. Сomputers that understand humans through text and voice are Sanofi’s solution for healthcare with many applications. Voice
technologies are used to detect, e.g. flu—or a general decline in condition—before it gets worse (e.g. pneumonia). A device in the
elderly person's home can analyze changes in a person's voice and detect symptoms early on. It helps homecare and home nurses
to detect their patients’ illness before they need hospital care.
Mentalab
5. Mentalab combines a wearable patch that can measure electrocardiogram biosignals continuously, with a cloud-based analysis service to
diagnose and monitor cardiac and respiratory conditions. The patch can be applied by patients directly, and worn throughout their daily
activities, while data is transmitted and analyzed seamlessly. In site-less clinical trials, this solution can increase patient engagement and
participation rates.
NeuroAdvise
6. NeuroAdvise is a clinical decision support tool available as a mobile application that helps physicians make better clinical decisions. Our
system can archive all demographic and clinical patient-related information in a classified manner. Data is currently stored without patient
identity according to time and date. NeuroAdvise algorithms are simulations of a clinician’s mental diagnostic process and most of the
important diagnostic factors are included in its comprehensive database. It only takes a few seconds for the user to access the list of
differential diagnosis, which are sorted in order of probability and unique for each patient. The system is flexible with unlimited capacity for
adding new symptoms, disorders and diagnostic tests.

CART

7. A ring-design cardio tracker, or CART, can provide continuous monitoring of vital signs in real-world clinical trials and can be worn easily in
daily life.
Source Sanofi

Deep Pharma Intelligence 85

 Most Innovative R&D Approaches of AI in Biopharma. Teva
Teva is investing in both original biologic medicines and in biosimilars (highly similar versions to specific innovator biologics) to help
patients around the world. We are focusing on treatments for the central nervous system, respiratory conditions, and in the field of
oncology. Teva uses the help of AI for development of ‘Single device location-algorithm pair’ for optimal treatment of impaired mobility
resulting from ageing and chronic disease as well as for digital technology, including body worn sensors.
In cooperation with IBM Research, Teva focuses on two key healthcare areas: the discovery of new treatment options and improving chronic disease
management.
Main focus areas: The way AI is used:
● to improve chronic disease management;
● to discover new treatment options;
● to repurpose already existing drugs.
Migraine
Cooperation:
● IBM Research
Cancer
Asthma

Central Nervous
System

Source Startuphub 7wdata

Deep Pharma Intelligence 86

 How Teva Uses AI in R&D?
In cooperation with IBM Research, Teva focuses on two key healthcare areas: the discovery of new treatment options and improving
chronic disease management. Teva’s AI projects are based on the IBM Watson Health Cloud, that is a health-data enabled
platform-as-a-service which is designed to help healthcare organizations derive individualized insights and obtain a more complete
picture of the many factors that can affect people’s health based on machine learning.
1. Teva has chosen the IBM Watson Health Cloud as a preferred global technology platform and managed to build solutions designed to help
millions of individuals worldwide with complex and chronic conditions such as asthma, pain, migraine and neurodegenerative diseases. In
addition, a joint Teva-IBM Research team will deploy Big Data and machine learning technology to create disease models and advanced
therapeutic solutions.
2. Watson is a groundbreaking cognitive computing platform that represents a new era of computing based on its ability to interact in natural
language, process vast amounts of Big Data to uncover patterns and insights, and learn from each interaction. The Watson Health Cloud
provides an open development platform for physicians, researchers, insurers and companies focused on creating health and wellness solutions.
3. IBM’s Global Business Services works closely with a Teva Analytics team to assess the data and the analytics model requirements for the Real
World Evidence e-health solution.
4. By building on the Watson Health Cloud, Teva is in a unique position to put the best information and insights in the hands of physicians, care
teams and patients, to empower treatment optimization for individuals and populations across the spectrum of acute and chronic conditions.
Watson provides Teva with better insights, real-time feedback and options for clinicians to consider to improve patient care.

Source 7wdata Teva

Deep Pharma Intelligence 87

 Most Innovative R&D Approaches of AI in Biopharma. Recursion Pharmaceuticals
Recursion Pharmaceuticals is a digital biology company, which applies AI for the development of its drug discovery platform and
pipeline.
The company is Reengineering drug discovery by taking a target-agnostic approach that combines automation, machine learning and
the world’s largest biological image dataset with a highly cross-functional team to discover transformative new treatments.
The company currently has 4 clinical stage programs and 6 preclinical candidates in its pipeline.

Main focus areas:

The way AI is used:

● for imaging analyses;

Genetic Disease
● to select and design chemical compounds (ReChem);
● to plan large, complex experiments (ReScreen);

Immunology ● to screen hundreds of thousands of drug compounds and cellular

disease models (ReScreenRun);
Inflammation ● to create digital mathematical signatures, or Phenoprints (ReRun);
● to compute the effectiveness of each drug compound in their assays, as
well as any unintended effects (ReAnalyze);
Infectious
Disease ● to model drug compound relationships (RePredict).

Deep Pharma Intelligence 88

 How Recursion Pharmaceuticals Uses AI in R&D?
The Recursion Pharmaceuticals’ platform is a continuous, iterative loop of "biology and bits" which combines wet lab biology experiments
that are executed automatically with machine learning algorithms computing the results in a cloud.
The Recursion drug discovery platform is based on five million images of human cells every week requires built-for-purpose components

Analyse & Design To generate its datasets Recursion Pharmaceuticals is primarily focused on:
Predict Experiment
Data reliability and relatability

By generating its own quality-controlled data, fit-for-the purpose of machine learning, Recursion is
minimizing data noise to be able to ensure comparability of data.

Generalized assay framework for broad biology:

Run workflow

The technology is based on the principle of inducing the disease states and screening of various cell types together with healthy cells using
fluorescent microscopy. By applying different substances, it’s possible to detect signals of potential drug-like molecules which return diseased cells to
a healthy state, as well as potential side-effects.

Scale and scale again through automation and innovation:

Recursion’s software engineers, screening technicians and data scientists work closely to create a platform which allow to decrease the costs of drug
discovery process. Recursion is trying to automatizate as much part of workflow as possible.

Deep Pharma Intelligence 89

 Most Innovative R&D Approaches of AI in Biopharma. OWKIN
Owkin is a predictive analytics company that was founded based on the belief that medical research must be collaborative, inclusive
and protect privacy. Today, Owkin is building a global research network leveraging federated learning that brings data scientists,
physicians, researchers and pharmaceutical companies together on a research platform that ensures data security and privacy.
Owkin is developing AI tools for medical researches to give patients access to safer and more effective therapies.

Main focus areas:

The way AI is used:

Oncology
● to understand why drug efficacy varies from patient to patient;
Immunology ● to enhance the drug development process;
● to identify the best drug for the right patient to improve treatment
outcomes.
Cardiovascular
Diseases

Deep Pharma Intelligence 90

 How Owkin Uses AI in R&D?
Owkin has created a unique research platform, and a portfolio of AI models and solutions.
The Owkin Loop is the heart of the Owkin Research Platform: it connects medical researchers with high-quality datasets from leading
academic research centers around the globe. Owkin Loop is powered by the two main components of Owkin’s Software Stack: Owkin
Studio, their machine learning platform, and Owkin Connect, their federated learning framework.

Owkin AI models

Owkin created a catalog of 30 live diseases models and has 40 additional models in the pipeline.These models differ from traditional black box
models because they are built using interpreted AI, which allows the company to move further in research and identify biomarkers responsible for
predictions. The discovery of new multimodal biomarkers is essential to identify new biological targets, optimize the design of clinical trials using
patients subgroups, and identify patients eligible for a particular treatments.

Data Enrichment Models

Designed for translational researchers and pathologists, these models link histology to molecular markers.

Outcome Prediction Models

Designed for translational researchers, development executives, and commercial staff, these models can be implemented throughout the clinical
drug development process to improve clinical trial design and evaluation, and to optimize product strategy.

Patient Identification Models

Designed for commercial and precision medicine leaders, these models help identify patients who will benefit from a particular treatment.

Deep Pharma Intelligence 91

 Most Innovative R&D Approaches of AI in Biopharma. Deep Genomics
Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies. The company has trained AI algorithms
to better understand and search new drug targets in human genomic sequences, specifically those that have been deemed “undruggable,” as
well as to design new Antisense Oligonucleotides (ASOs) drugs.

Main focus areas:

The way AI is used:

● to find drug candidates (ASOs) with desirable properties;

● to predict molecular phenotypes alterations, such as transcription,
Metabolic Disease splicing, translation and protein binding;
(Wilson Disease)
● to produce On-target and genome-wide off-target effect data, cell viability
data and animal toxicity data.
Genetic Disease

Ophthalmologic
Disease

Deep Pharma Intelligence 92

 How Deep Genomics Uses AI in R&D?
Deep Genomics use its AI Workbench to rapidly discover and develop genetic therapies, and to do so with a increasing success rate.

Genetic Medicines. Deep Genomics’ AI Workbench enables them to efficiently find drugs with desired properties. The company is
focussing on the development and marketing of antisense oligonucleotide therapies that target the disrupted genes that cause
diseases at the level of RNA or DNA. Deep Genomics is predicting altered molecular phenotypes, such as transcription, splicing,
translation and protein binding that may caused genetic diseases.

The Deep Genomics platform is able to produce On-target and genome-wide off-target effect data, cell viability data and animal
toxicity data for every compound. They also collect data related to biomarkers. All data is processed using feedback loops.

The Deep Genomics’ research works have appeared in Science, Nature, Nature Genetics, Nature Medicine, Nature Methods,
Proceedings of the IEEE, NIPS, Bioinformatics, RECOMB and ISMB.

Project Saturn has proved the utility of Deep Genomics’ AI platform

In Project Saturn, the Deep Genomics’ team was using their platform to evaluate over 69 billion oligonucleotide molecules against 1 million targets in
silico, to generate a library of 1000 compounds that were experimentally verified to manipulate cell biology as had intended.

Deep Pharma Intelligence 93

 Most Innovative R&D Approaches of AI in Biopharma. AI Therapeutics
AI Therapeutics is an AI-driven company with a unique ability to match drugs according to indications and prosecute through clinical
development. AI Therapeutics’ revolutionary approach to drug discovery and development has led to clinical trials of three drugs.

The way AI is used:

Main focus areas:
● to precisely match drugs to diseases;
Rare Disease
● to identify the best care for individual patients.

Cancer AI Therapeutics has developed a new Guardian Angel™ artificial

intelligence algorithm that has learned to predict new therapies for
diseases with unprecedented accuracy. Guardian Angel ™ combines public
and proprietary data and is designed to search for drugs for any indication.
Drugs currently in clinical trials target:

- Lymphangioleiomyomatosis;
- B-cell non-Hodgkin lymphoma;
- acute myeloid leukemia;
- amyotrophic lateral sclerosis;
- facial angiofibroma;
- COVID-19

Deep Pharma Intelligence 94

Industry
Developments
2020

DEEP
PHARMA
INTELLIGENCE
 Biggest Investment Deals of Q4 2019 — 2020

Some of the major investment deals included:

● insitro with their $143 million (Series B);

● XtalPi with $319 million (Series C);
● Atomwise with $123 million (Series B);
● Recursion Pharmaceuticals with $239 million (series D);
● AbCellera with the sum of $105 million (Series B).

If AI companies provide more evidence and successful studies

demonstrating the functionality and value of their solutions, especially
regarding the COVID-19 crisis, investors and pharma partners will
probably consider increasing the number and sums of the investment
deals in the future.
Additionally, the growing biotechnology industry is expected to provide
growth opportunities for AI companies in terms of collaborations and
partnerships.

Deep Pharma Intelligence 96

 Industry Developments Q4 2019 — 2020
NOV ― AI start-up, Deep6, secured $17 Million from Point72 Ventures to accelerate patient recruitment. According to the Forbes, the Deep6’s
2019 AI-powered platform is valued at $50 million and is able to find patient for the clinical trial in minutes, whereas this process usually takes
months. Deep6 applies natural language processing to extract data from electronic medical records, pathology reports, physicians notes,
and other documentation.
― AstraZeneca intends to open AI and drug research centers in China and make a $1 billion capital infusion into Chinese biotech
innovations. The global R&D center will be opened in Shanghai, where research will be focused on diseases prevalent in China. China is
already the second market for AstraZeneca after the United States, and sales in China continue to grow.
DEC ― Page raised $45 M to accelerate cancer research. The round was led by Healthcare Venture Partners, with the participation of previous
2019
investor Breyer Capital, Kenan Turnacioglu, and others. Page's artificial intelligence technology for mapping cancer pathology was
developed by Dr. Thomas Fuchs, also known as the "father of computational biology." The company also has access to the repository of
25 million pathology slides owned by the Memorial Sloan Kettering Cancer Center, which is the perfect material to feed the AI engine.
JAN ― Exscientia has entered a 3-year $266 million agreement with Bayer. The partnership will leverage AI to accelerate the discovery of small
molecules candidates programs for oncology and cardiovascular diseases.
― The first drug developed using artificial intelligence by Exscientia in partnership with Sumitomo Dainippon Pharma is entering Phase I
clinical trial for the treatment of the obsessive-compulsive disorder. The drug, called DSP-1181, was discovered using Exscientia
proprietary Centaur Chemist technology. The clinical trials will start in Japan, and Sumitomo Dainippon Pharma will add DSP-1181 to its
psychiatry and neurology pipeline.
― Deep Genomics, a Toronto-based start-up, raised $40M in Series B funding round. The round was led by Future Ventures with the
participation of Amplitude Ventures, Khosla Ventures, Magnetic Ventures, and True Ventures. The Deep Genomics software, Saturn, is
used to identify and better understand drug targets, especially ones that are thought to be undruggable. The company hopes two
programs will be advanced to the IND application in 2020.

Deep Pharma Intelligence 97

 Industry Developments Q4 2019 — 2020
― Schrödinger enters a 5-year agreement with Bayer to work on a new virtual platform for small molecules design, which will be able to
design and screen synthetically feasible compounds. The collaboration will be built on Schrödinger’s machine learning and molecular
design technologies, while Bayer will provide in silico model for predicting the pharmacological properties of the molecules.
― Insilico will work with Pfizer to collect real-world-data for targets in multiple therapeutic areas.
FEB ― Schrödinger, a chemical software company, raised $232M in IPO. Several drug candidates that are currently developing by the
pharmaceutical companies were discovered using Schrödinger’s software. In the future, the company will focus on the expanding of its
software applications and bringing up new customers. The company is also developing its own pipeline for oncological indications.
― Scientists from MIT discovered one the most powerful antibiotic known to date using Artificial Intelligence. The algorithm was trained on
2500 existing antibiotics and was able to screen more than one hundred million molecules in several days. This is an absolute
breakthrough in antibiotic discovery, the area that is now facing the problem of multi-resistance of bacteria strains. The new antibiotic,
called halicin, was able to kill 35 types of potentially deadly bacteria.
― Lunit, a Korean start-up, has raised $26M in its series C funding led by Korea’s Shinhan Investment, followed by InterVest, IMM
Investment, Kakao Ventures, and China’s Legend Capital of Lenovo Group. With the new funding, Lunit plans to increase the global sales
of its AI products — Lunit INSIGHT CXR for analyzing chest X-rays images and Lunit INSIGHT MMG for mammography. Additionally, the
fund will support the development of the AI tool for analyzing cancer pathological tissue slides — Lunit SCOPE.
― BenchSci raised $22 million in financial round B, bringing the company to $45 million of total funding. Besides raising a new round, the
company announced the launch of its new AI-powered reagent selection product and the expansion of the agreement with Novartis.
Another BenchSci’s product, AI-Assisted Antibody Selection, uses AI to search for data on published antibodies and can select antibodies
in 30 seconds instead of 12 weeks. The fund will help BenchSci to develop its products and accelerate drug testing.
― Qure.ai has secured $16 million from Sequoia Capital India and Singapore-based MassMutual Ventures Southeast Asia. Qure.ai is
artificial intelligence provider of automated interpretation of radiology images: X-rays, CTs, and MRI scans.

Deep Pharma Intelligence 98

 Industry Developments Q4 2019 — 2020
― Atomwise enters into a research collaboration with a Korean clinical-stage biotech Bridge Biotherapeutics. Atomwise will apply
MAR
structure-based AI technology to evaluate and initiate programs for Pellino E3 ubiquitin ligases and other targets.
― Alibaba Cloud launched a series of AI solutions to help fight the coronavirus infection. The three of them are available for free for research
institutes and medical specialists worldwide. The solutions were created by the joint work of Alibaba Cloud, Alibaba DAMO Academy, and
DingTalk. These include Epidemic Prediction Solution, CT Image Analytics Solution, Genome Sequencing for Coronavirus Diagnostic
Solution, and Elastic High-Performance Computing (E-HPC) Solution for Life Sciences. The last was built especially for Computational and
AI-driven drug discovery, as well as for other life science applications, and has been applying by 20 research groups in China.
― Schrödinger enters a 3-year collaboration with Google Cloud to leverage the supercomputer power for speeding up Schrödinger’s
molecular modeling platform. Schrödinger has ambitious plans to hire thousands of professors to be able to run simulations for billion
compounds per week. The agreement is following Schrödinger’s IPO last month, where the company raised $232 million. The purpose of
this collaboration is targeting DNA damage response pathways and related cancers with small molecules. The company has plans to start
IND-enabling, preclinical studies in 2021.
― Reverie Labs enters a multi-target partnership with Roche to discover next-generation kinase inhibitors. The company will apply its
expertise to screen, generate hits, and perform hit-to-lead optimization together with scientists at Roche and Genentech. The kinases are
perfect objects to drain ML models, as there is a lot of published data about them.
APR ― BenevolentAI predicted the repurposed drug for treating coronavirus, that entered Phase III clinical trials. This drug, called Baricitinib, was
developed by Eli Lilly and Incyte and approved for the treatment of rheumatoid arthritis under the “Olumiant” name. Benevolent claims that
it took only 1,5 hours to run it’s AI algorithms and 3 days of manual work to predict this molecule.
― Insilico collaborates with Boehringer Ingelheim to help to discover new targets within the Boehringer’s Research Beyond Borders initiative,
created to expand areas and the geographies of the company’s drug discovery collaborations. Insilico will provide its generative models
and machine learning programs and give access to its new Pandomic platform to facilitate visualization of omics data connected to
signaling pathways and disease profiling.

Deep Pharma Intelligence 99

 Industry Developments Q4 2019 — 2020
― insitro, a machine learning-driven drug discovery company, raised $143 million in Series B financing. The round was led by Andreessen
MAY
Horowitz, with the participation of the Canada Pension Plan Investment Board (CPP Investments) and other funds. The investment will be
used to further develop the company's technology and automation, which allows the in-house generation of a massive amount of
biological data to train algorithms and built predictive disease models. The company also plans to advanced biomarker development and
personalized therapeutics.
― AbCellera received $105 Million Series B Financing from OrbiMed, DCVC Bio, and an investor syndicate that includes Viking Global
Investors, Peter Thiel, Founders Fund, Eli Lilly, University of Minnesota, and Presight Capital. By applying AI, AbCellera is transforming the
area of antibody discovery. The investments will be used to improve and expand their technology creating new tools and to develop new
therapeutic modalities. AbCellera successfully developed 55 drug candidates, including targeting GPCRs and ion channels.
― Exscientia has raised $60M in financial round C. The round was led by Novo Holdings, Evotec, Bristol Myers Squibb, and GT Healthcare
Capital. Proceeds will be used to expand the company’s drug discovery pipeline and to built “full-stack” capabilities. Additionally,
Exscientia plans to expand its presence to the USA market. The company is also involved in the coronavirus pandemic fight, as it partnered
with Calibr and Diamond Light Source to develop an anti-Sars-Cov-2 treatment.
― Boehringer Ingelheim partners with BERG to investigate inflammatory diseases, particularly inflammatory bowel disease and Crohn’s
disease, find the causes, develop new biomarkers, targets, and new drugs. BERG CEO Niven Narain emphasizes that it is a biology
company that has wet lab facilities for data generation, applies a mathematical approach distinct from machine learning, and has 2 drugs
in companies portfolio that have been advanced to the clinic.
― Immunai has raised $20M in a seed round from Viola Group and TLV Partners to map the entire immune system. The startup combines
machine-learning and single-cell technologies to map immune cells and their functions. The technology was developed to profile immune
cells from blood samples, support biomarker discovery, and investigate the cellular response to the cancer immunotherapies. This
research will help to improve immunotherapies, as even a slight variation in immunotherapies can bring to dramatically different patient
responses.

Deep Pharma Intelligence 100

 Industry Developments Q4 2019 — 2020
― Owkin raised $18 M in Series A financing. The investment was made by Mubadala Capital and Bpifrance, through the bank’s Large
JUNE
Venture fund. The company will continue to develop its platform aimed to make the drug discovery process more collaborative. The
platform utilizes imaging, genomic, and clinical data and connects researchers from industry and academia, clinicians, and other players.
― Cyclica secured $17M in financing round B from Drive Capital with the participation of Chiesi Farmaceutici, GreenSky Capital, and
members of Cyclica's management team. This Toronto-based start-up developed two platforms — Ligand Design and Ligand Express that
predict molecular properties via applying deep learning technology.
― Google partners with a fresh start-up, ZebiAI, to launch Chemome initiative. Previously, Google and X-Chem demonstrated a new approach
for finding biologically active compounds — a combination of DNA encoded libraries screening technology and virtual screening using a
graph convolutional neural network developed by Google.
JULY ― Yale School of Medicine and AI therapeutics launched Phase II clinical trials of a new anti-Sars-Cov-2 drug “LAM-002A”. The drug, also
called apilimod, has been shown to prevent the virus from entering cells. Previously LAM-002A proved safety for the treatment of
lymphoma and autoimmune diseases, and it is being repurposed for coronavirus treatment after AI Therapeutics screened about 13,000
existing drugs against two strains of Sars-Cov-2. The study results were published in Nature.
― Lantern Pharma announced an agreement with leading contract manufacturing companies to prepare for the start of Phase II and Phase I
clinical trials of its two anti-cancer drug candidates. The first candidate - LP-300, that was developed against non-small cell lung cancer
among never-smoker, is entering the Phase II clinical trial stage. The second candidate, LP-184, developed to treat a specific type of solid
tumor and glioblastoma multiforme, is anticipated to enter Phase I stage at the end of 2021 or in early 2022. Latent hopes that annual
sales of this drug will be accounted for $3.5 billion USD by 2025. Both drug candidates were created using RADR® A.I. platform, which
combines ML methods, genomics, and computational biology to unveil drugs MoA and discover biomarkers for precision oncology.
― Global Open Science project COVID Moonshot was launched by the international consortium of industrial and academic partners,
including AI-driven startup PostEra. The goal of this initiative is to create novel anti-COVID drugs, including attempts to block SARS-Cov-2
main protease. The project is managed by PostEra, the start-up that applies AI to prioritize ideas and find optimal synthesis routes.

Deep Pharma Intelligence 101

 Industry Developments Q4 2019 — 2020
― Atomwise raised $123 million in a round B of financing led by B Capital Group and Sanabil Investments, also including DCVC, BV, Tencent,
AUG
Y Combinator, Dolby Family Ventures, AME Cloud Ventures, and 2 top insurance companies. The investment will be used to start the
company’s own drug discovery pipeline, extend the market, and develop new partnerships with pharmaceutical companies.
― IBM introduced a new cloud platform — RoboRXN, which is a free AI-enabled chemical service for the prediction of molecule interactions
and the discovery of new drugs. The platform will be primarily used to discover compounds against coronavirus proteins. RoboRXN
combines artificial intelligence, cloud technologies, and automation for organic chemistry. Additionally, new organic reactions might be
discovered using the platform. The platform can work remotely and analyze commands copied from literature by chemists.

SEP ― Chinese tech giant Baidu plots an AI-baked drug discovery startup, looking for investors to collectively infuse $2B in. The start-up is
planned to be a standalone company, but not Baidu’s subsidiary. Baidu has previously invested in other AI startups — Atomwise, Insilico,
and Polaris Biology.
― XtalPi, a Chinese pharmaceutical tech company, has raised $319M in funding round C, which was led by SoftBank Vision Fund 2, PICC
Capital, and Chinese firm MorningSide Venture Capital. The funding will be used for the further development of XtalPi’s Intelligent Digital
Drug Discovery and Development (ID4) platform, which combines artificial intelligence, quantum mechanics, and high-performance cloud
computing algorithms to predict activities of small molecule drug candidates, solid-form selection, and other critical aspects of drug
development.
― Recursion Pharmaceuticals raises $239M in series D funding round. This includes $50 million from Bayer’s investment arm Leaps and
funds from Casdin Capital, Baillie Gifford, and others. Recursion has also entered in drug discovery collaboration with Bayer to develop
new treatments against fibrotic diseases of different organs. Recursion will receive $30M of upfront payment and could potentially receive
$100M milestones for each discovery program and royalties on future sales.
― The MELODY (Machine Learning Ledger Orchestration for Drug Discovery) project initiated by 10 major pharmaceutical companies
achieved its first goal — the deploying of a drug discovery platform. Together with Nvidia and Owkin, these companies are building the
federated learning solution where AI can be trained on desperate datasets from different sites without the need to collect data together.

Deep Pharma Intelligence 102

 Industry Developments Q4 2019 — 2020
― Exscientia teams up with Huadong Medicine for the small molecules oncology program. The project is focused on DNA damage repair
SEP
and specifically investigates the transcription control of DNA damage response genes, which disruption leads to the mutation
accumulations. Both companies will share the responsibilities for the project. To design new molecules, Exscientia will apply the Centaur
Chemist AI platform, which allows to design new molecules and prioritize them for synthesis. Meanwhile, Huadong Medicine will apply its
expertise to generate data and improve Exscientia’s AI design in a closed-loop cycle.
― Insilico Medicine is launching a new target and drug discovery platform Pandomics, that is the part of the Pharma.ai. The platform
enables to analyse and interpret OMICS data without having an experience in bioinformatics and computational biology. The technology
has been developing for 6 years, and proved itself in several collaborations and Insilico’s own drug development programs.
OCT ― Taisho Pharmaceutical and Insilico have entered into a research collaboration to identify novel therapeutics against aging. Insilico
Medicine will utilize both the target discovery and generative chemistry parts of its Pharma.AI platform in this collaboration. It will use its
proprietary Pandomics Discovery Platform to identify novel targets for senolytic drugs and Chemistry42 platform for a molecular
generation.

Deep Pharma Intelligence 103

Appendix:
List of Entities
 240 Companies Applying AI for Drug Discovery and Advanced R&D

1. A2A Pharmaceuticals 21. Ariana Pharma 41. C4X discovery

2. Accutar Biotech 22. Arrakis Therapeutics 42. Cambridge Cancer Genomics
3. Acellera 23. Arzeda 43. CaroCures
4. Acorn AI 24. Athelas 44. Causaly
5. AcuraStem 25. Atomwise 45. Cellarity
6. Aetion 26. Auransa Inc. 46. Celsius Therapeutics
7. AI Therapeutics 27. BenchSci 47. Chempass
8. Ai-biopharma 28. BenevolentAI 48. Clinithink
9. AiCure 29. Berg LLC 49. Cloud Pharmaceuticals
10. Aigenpulse 30. Berkeley Lights 50. CloudMedX
11. Alector 31. BioAge Labs 51. Collective Scientific
12. Alphanosos 32. Biodesix 52. Concerto HealthAI
13. Anima Biotech 33. Biorelate 53. Cotinga Pharmaceuticals
14. Antidote 34. BioSymetrics 54. Cyclica
15. Antiverse 35. Biotx.ai 55. CytoReason
16. ApexQubit 36. Biovista 56. Cytox
17. Aqemia 37. BioXcel 57. Data2Discovery
18. Arbor Biotechnologies 38. Bioz 58. Data4Cure
19. Arctoris 39. BlackThorn Therapeutics 59. Datavant
20. Ardigen 40. BullFrog AI 60. Deep 6 AI

Deep Knowledge Analytics 105

 240 Companies Applying AI for Drug Discovery and Advanced R&D

61. Deep Genomics 81. Erasca 101. Healx

62. Deep Intelligent Pharma 82. Euretos 102. HelixAI
63. DeepLens 83. Evaxion Biotech 103. iCarbonX
64. DeepMatter 84. Evid Science 104. Ideaya Biosciences
65. DeepMind Health 85. Evoke Neuroscience 105. Iktos
66. DeepPhenome 86. Evolutionary Genomics 106. Imagia
67. Delta4 AI 87. Exscientia 107. Inato
68. Denovicon Therapeutics 88. FAR Biotech 108. Indegene
69. Desktop Genetics 89. FDNA 109. Ingentium
70. DEXSTR 90. Fetch Biosciences 110. Innophore
71. Dristi.ai 91. Flatiron Health 111. Innoplexus
72. E-therapeutics 92. Foundation Medicine 112. Inside DNA
73. Eigengene 93. Frontier Medicines 113. Insilico Medicine
74. Elucidata 94. GenFit 114. Insitro
75. Emerald Cloud Lab 95. Genialis 115. Intellegens
76. Empiric Logic 96. Globavir 116. Intelligencia
77. Engine Biosciences 97. GNS Healthcare 117. Interprotein
78. EntheogeniX Biosciences 98. Gritstone Oncology 118. Intomics
79. Entropica Labs 99. GTN Limited 119. InveniAI
80. Envisagenics 100. Haystack Sciences 120. InVivo AI

Deep Knowledge Analytics 106

 240 Companies Applying AI for Drug Discovery and Advanced R&D

121. Iris.ai 141. Micar Innovation 161. Olaris

122. iTeos Therapeutics 142. Micrographia Bio 162. omicX
123. Just Biotherapeutics 143. Mind the Byte 163. OneThree Biotech
124. Juvenescence AI 144. Molomics 164. Optibrium
125. Keen Eye 145. Molplex 165. Owkin
126. Kite Pharma 146. Mozi AI health 166. Paradigm4
127. KYAN Therapeutics 147. Nanna Therapeutics 167. PathAI
128. Kyndi 148. Neon Therapeutics 168. PatSnap
129. LabGenius 149. NetraMark 169. Pending AI
130. LabTwin 150. Nference 170. Pepticom
131. Lantern Pharma 151. Nimbus Therapeutics 171. Peptone
132. Linguamatics 152. Notable 172. Percayai
133. Longenesis 153. Novoheart 173. Perceiv Research
134. MAbSilico 154. nQ Medical 174. Pharma.AI
135. Massive Bio 155. Nucleai 175. Pharmacelera
136. MediBIC Group 156. NuMedii 176. PharmCADD
137. MedView Technologies 157. Numerate 177. Pharnext
138. Mendel.ai 158. Nuritas 178. Pharos iBT
139. Menten Biotechnology Labs 159. OccamzRazor 179. Phenomic AI
140. Meta 160. OKRA Technologies 180. Plex Research

Deep Knowledge Analytics 107

 240 Companies Applying AI for Drug Discovery and Advanced R&D

181. PostEra 201. Sangamo BioSciences 221. TARA Biosystems

182. Precisionlife 202. Satalia 222. Tempus
183. Prognica Labs 203. Schrodinger 223. TeselaGen
184. Proscia 204. SEngine Precision Medicine 224. ThoughtSpot
185. ProteinQure 205. Sensyne Health 225. TrialJectory
186. Qrativ 206. Sigma Technologies 226. Turbine AI
187. Quantitative Medicine 207. Silexon 227. TwoXAR
188. Quertle 208. Silicon Therapeutics 228. uBiome
189. Qulab 209. Sirenas 229. Unnatural Products
190. Recursion Pharmaceuticals 210. Sophia Genetics 230. Verge Genomics
191. Relay Therapeutics 211. Sparrho 231. VERISIM Life
192. Remedium AI 212. Spring Discovery 232. Virogin
193. Repurpose.AI 213. Standigm 233. Virvio
194. Researchably 214. StoneWise 234. Vyasa Analytics
195. Resonant Therapeutics 215. Strateos 235. WinterLight Labs
196. Reveal Biosciences 216. Structura Biotechnology 236. WuXi NextCODE
197. Reverie Labs 217. Synergy Pharmaceuticals 237. Xbiome
198. ReviveMed 218. Syntekabio 238. XtalPi
199. Roivant Sciences 219. Synthace 239. ZappRx
200. Saama 220. Systems Oncology 240. ZebiAI

Deep Knowledge Analytics 108

 600 Investors - AI for Drug Discovery and Advanced R&D

1. 415 22. Agent Capital 42. AME Cloud Ventures

2. 10x Group 23. AGORANOV 43. Amgen Ventures
3. 11.2 Capital 24. AJS Investments 44. Amplify Partners
4. 180 Degree Capital 25. Alan Cohen 45. Amplitude Venture Capital
5. 1984 Ventures 26. Alchemist Accelerator 46. Andreessen Horowitz
6. 360 Capital Partners 27. Alector 47. Angels in MedCity
7. 3W Partners Capital 28. ALevel Capital 48. Anges Quebec
8. 500 Startups 29. Alexa Accelerator, Powered by Techstars 49. Angivest Ventures
9. 5AM Ventures 30. Alexa Fund 50. Apeiron Investment Group
10. 6 Dimensions Capital 31. Alexandria Real Estate Equities 51. Aquarius Equity Partners
11. 7BC Venture Capital 32. Alexandria Venture 52. Arab Angel Fund
12. 8VC 33. AllBright 53. Arboretum Ventures
13. A-Level Capital 34. Alpha Edison 54. ARCH Venture Partners
14. Abstract Ventures 35. Alphabet 55. Arkitekt Ventures
15. Accel X 36. ALS Investment Fund 56. ArrowMark Partners
16. Accelmed Growth Partners 37. Alta Partners 57. Artis Ventures (AV)
17. Access Industries 38. Altitude Life Science Ventures 58. Arzeda
18. AcuraStem 39. Altos Ventures 59. Asahi Kasei
19. Advantage Capital 40. Amadeus Capital Partners 60. Asset Management Ventures (AMV)
20. Advent Life Sciences 41. Amazon 61. Astellas Pharma
21. Afore Capital 62. Astia Angels

Deep Knowledge Analytics 109

 600 Investors - AI for Drug Discovery and Advanced R&D

63. AstraZeneca 84. Bill Tai 105. Cambia Health Solutions

64. Atinum Investment 85. Bioeconomy Capital 106. Canaan Partners
65. Atlas Venture 86. Biomatics Capital Partners 107. Canada Pension Plan Investment Board
66. Atomico 87. Bios Partners 108. Cantos
67. Aurinvest 88. Biotechnology Value Fund 109. Capital One Growth Ventures
68. B Capital Group 89. Bioverge 110. Carrick Capital Partners
69. Babel Ventures 90. Black Diamond Ventures 111. Cascade Investment
70. Baidu 91. BlackRock 112. Casdin Capital
71. Baidu Ventures 92. Bloomberg Beta 113. Catalyst Health Ventures
72. Baillie Gifford 93. Blue Bear Ventures 114. Catapult Ventures
73. Baird Capital 94. Bold Capital Partners 115. Cathay Innovation
74. Bakken & Baeck 95. BootstrapLabs 116. CedarsSinai Accelerator
75. Balderton Capital 96. Boundary Capital Partners LLP 117. Celgene
76. Bangarang Group 97. Boxer Capital 118. Chiesi Pharmaceuticals
77. Baron Capital Management 98. Bpifrance 119. China Bridge Capital
78. Basis Set Ventures (BSV) 99. BR Ventures 120. China Canada Angel Alliance
79. BCF Ventures 100. Brightspark Ventures 121. China Equity
80. BDC Venture Capital 101. BristolMyers Squibb 122. China Life Healthcare Fund
81. Beast Ventures 102. btov Partners 123. Cigna Ventures
82. Big Pi Ventures 103. Builders VC 124. Cisco
83. Bill & Melinda Gates Foundation 104. Caffeinated Capital 125. Citrix Startup Accelerator

Deep Knowledge Analytics 110

 600 Investors - AI for Drug Discovery and Advanced R&D
126. Citrix Systems 147. D.A. Wallach Founding Partner 168. Draper Associates
127. City Hill Ventures 148. Daniel Curran 169. Draper Dragon
128. Civilization Ventures 149. Darling Ventures 170. Driehaus Capital Management
129. Clal Biotechnology Industries 150. Darrin Disley 171. Drive Capital
130. Claremont Creek Ventures 151. Data Collective DCVC 172. DROIA
131. Clarus Ventures 152. DCM Ventures 173. Dynamk Capital
132. CLI Ventures 153. Debiopharm Innovation Fund 174. EASME EU Executive Agency for SMEs
133. CM-CIC Capital Finance 154. Deep Knowledge Ventures 175. Echo Health Ventures
134. Colt Ventures 155. Deerfield 176. EcoR1 Capital
135. Conversion Ventures LLC 156. Deerfield Capital Management 177. EDBI
136. Cormorant Asset Management 157. Density Ventures 178. Eight Roads Ventures
137. Cosine 158. Dentsu 179. Elad Gil Cofounder @ Color
138. Cota Capital 159. Development Bank of Wales 180. Emerald Development Managers
139. Creative Destruction Lab 160. Dexcel Pharma 181. Emerge Education
140. CRG L.P. 161. DFJ 182. Endeavour Vision
141. Crowdcube 162. DFJ Growth 183. Endure Capital
142. CRV 163. DHVC 184. ENISA
143. CTI Life Sciences Fund 164. Digital Science 185. Enterprise Ireland
144. Cultivian Sandbox Ventures 165. DNA Capital 186. Entrepreneur First
145. curative ventures 166. Dolby Family Ventures 187. EPIC Capital
146. D. E. Shaw Research 167. Dorm Room Fund 188. EPIC Ventures

Deep Knowledge Analytics 111

 600 Investors - AI for Drug Discovery and Advanced R&D
189. Esperante Ventures 210. Flybridge 231. Geodesic Capital
190. Euclidean Capital 211. Flybridge Capital Partners 232. Gi Global Health Fund LP
191. European Investment Bank (EIB) 212. Fond Vives II 233. GlaxoSmithKline
192. European Union 213. Foresite Capital 234. Global Brain Corporation
193. Evotec 214. Formic Ventures 235. Global Founders Capital
194. F-Prime Capital 215. Foundation Capital 236. GM&C Life Sciences Fund
195. Fairhaven Capital Partners 216. Foundation for Technological Innovation 237. GNI Group
196. Farzad (Zod) Nazem 217. Founders Factory 238. GNS Healthcare
197. Federated Kaufmann Fund 218. Founders Fund 239. Golden Ventures
198. Felicis Ventures 219. FPrime Capital 240. Goldman Sachs
199. Fenox Venture Capital 220. Frazier Healthcare Partners 241. Goodman Capital
200. Fidelity 221. FREES FUND 242. Google
201. Fifty Years 222. Fund+ 243. Government of Canada
202. Finance Wales 223. FundersClub 244. Government Of Quebec
203. Financiere Boscary 224. Fusion Fund 245. GPG Ventures
204. Finorpa 225. Future Fund 246. Gradient Ventures
205. First Round 226. Future Ventures 247. Great Oaks Venture Capital
206. First Round Capital 227. GEIF Ventures 248. Green Park & Golf Ventures
207. First Star Ventures 228. General Atlantic 249. GreenSky Capital
208. Flare Capital Partners 229. General Catalyst 250. Greenspring Associates
209. Fly Ventures 230. Generation Investment Management 251. Greylock

Deep Knowledge Analytics 112

 600 Investors - AI for Drug Discovery and Advanced R&D
252. Grok Ventures 272. HOF Capital 293. Intel Capital
253. Groupe Roski 273. Holtzbrinck Digital 294. Intermountain Ventures
254. Grove Ventures 274. Horizon Healthcare Services 295. International Private Bank (IPB)
255. GV 275. Horizons Ventures 296. Invoke Capital Partners
256. Gyan Kapur 276. Human Capital 297. Invus
257. Hack VC 277. Hyperplane Venture Capital 298. IPGL
258. Hacking Health Accelerator 278. IA Ventures 299. IQ Capital
259. Hanhai Studio 279. IBM 300. Ireland Strategic Investment Fund
260. HBM Partners 280. IDG Capital 301. IT-Farm
261. Health Velocity Capital 281. Idinvest Partners 302. J. Hunt Holdings
262. Health Wildcatters 282. iGan Partners 303. James Hong
263. Healthbox 283. Illumina Ventures 304. Jiantou Huawen Investment
264. HealthInc 284. Inbio Ventures 305. JMI Equity
265. Heritage Provider Network 285. INDEX: Design to Improve Life 306. Johnson & Johnson Innovation
266. Hewlett Packard Pathfinder 286. IndieBio 307. Juvenescence
267. HIGHLINEvc 287. Industry Ventures 308. Kakao Ventures
268. Hike Ventures 288. Initialized Capital 309. Kapor Capital
269. Hillhouse Capital Group 289. Innospark Ventures 310. Karlin Ventures
270. Hitachi 290. Innovate UK 311. KdT Ventures
271. Hiventures Investment Fund 291. Inovia Capital 312. Khosla Ventures
292. Institut Català de Finances (ICF) 313. Kima Ventures

Deep Knowledge Analytics 113

 600 Investors - AI for Drug Discovery and Advanced R&D
314. Kingsley Advani 334. Lilly Asia Ventures 354. Matrix Partners
315. Kleiner Perkins 335. Lilly Ventures 355. Maverick Ventures
316. Konstantin von Unger 336. Lim Teck Lee 356. Mayo Clinic
317. Korea Tech Incubator Program 337. Linden Mobile Ventures 357. Mayo Clinic Ventures
318. KTB Network 338. Liquid 2 Ventures 358. MedTech Innovator
319. La Famiglia 339. London CoInvestment Fund 359. Menlo Ventures
320. LabCorp 340. Lucas Venture Group 360. Merck
321. Lakestar 341. Lundbeck 361. Merck Global Health Innovation Fund
322. Lane Bess 342. Lux Capital 362. Mercury Fund
323. Lansdowne Partners 343. LVL1 Group 363. Michael Antonov
324. Lanza Tech Ventures 344. M12 364. Michael J. Fox Foundation
325. LaunchCapital 345. MACSF 365. Microsoft
326. Laurion Capital Management 346. Madrona Venture Group 366. Midven
327. LB Investment 347. Magnetic Ventures 367. Minneapolis Heart Institute Ventures
328. LeFrak 348. Manchester Tech Trust Angels 368. Mission and Market
329. Life Sciences Angel Network 349. Marathon Venture Capital 369. Mission Bay Capital
330. Lifeforce Capital 350. Marketplace Funds 370. MIT delta v
331. LifeSci Venture Partners 351. Masa Life Science Fund 371. MITS Fund
332. Lightspeed Venture Partners 352. MassChallenge 372. Mitsui & Co
333. Lightstone Ventures 353. Matrix Capital Management 373. Monsanto Growth Ventures (MGV)

Deep Knowledge Analytics 114

 600 Investors - AI for Drug Discovery and Advanced R&D

374. Morgan Noble 394. Nir Kalkstein 414. Palisades Growth Capital
375. MPM Capital 395. NJF Capital 415. Panache Ventures
376. MRL Ventures Fund 396. Nordic Impact 416. Parinvest
377. Mubadala Capital Ventures US 397. Normandie Participations 417. Partner Fund Management
378. Mubadala Investment Company 398. Northleaf Capital Partners 418. Pavilion Capital
379. National Institutes of Health 399. Northpond Ventures 419. Paxion Capital Partners
380. NDRC 400. Northstar Ventures 420. Pear VC
381. Neoteny 401. Novaquest Capital Management 421. Pentech Ventures
382. Nest.Bio Ventures 402. Novartis 422. Perceptive Advisors
383. Nesta Ventures 403. Novartis Venture Fund 423. Perivoli Innovations
384. New Enterprise Associates 404. NPIF Maven Equity Finance 424. Pfizer
385. New Leaf Venture Partners 405. NVIDIA 425. Pfizer Venture Investments
386. New Wave Ventures 406. Oak HC/FT 426. Pi Campus
387. New York Presbyterian Ventures 407. Obvious Ventures 427. Pillar Companies
388. New York State 408. OrbiMed 428. Pinnacle Ventures
389. New York State of Opportunity 409. Origin Capital 429. Pioneer Fund
390. NewDo Venture 410. OS Fund 430. PivotNorth Capital
391. Nex Cubed 411. Oseo 431. Plug and Play
392. Nextech Invest 412. OUP (Osage University Partners) 432. Polaris Partners
393. Nikon 413. Overkill Ventures 433. PP Capital

Deep Knowledge Analytics 115

 600 Investors - AI for Drug Discovery and Advanced R&D
434. Prefix Capital 454. Revolution 474. Sapphire Ventures
435. Premier Partners 455. Rho Canada Ventures 475. Scale Asia Ventures
436. Primary Venture Partners 456. Right Side Capital Management 476. Schooner Capital
437. Pritzker Group Venture Capital 457. Rising Tide 477. Schrodinger
438. Qiming Venture Partners 458. Riva Capital 478. SciFi VC
439. QTV Financial 459. Rivas Capital 479. Sea Lane Ventures
440. Qualgro VC 460. Riverbank Capital Securities 480. Section 32
441. QVT Financial 461. Robin Hood Ventures 481. Seedcamp
442. RA Capital Management 462. Roche 482. Seneca Partners
443. Radical Ventures 463. Roche Venture Fund 483. Sequoia Capital
444. Ramen Ventures 464. Rock Health 484. Sequoia Capital China
445. Razor's Edge Ventures 465. Roivant Sciences 485. Seraph Group
446. Real Ventures 466. Romulus Capital 486. Serena
447. Redalpine 467. RTW Investments LLC 487. Service Provider Capital
448. Redmile Group 468. S.R.I.W. 488. ServiceNow
449. Redpoint 469. SAIF Partners 489. Seventure Partners
450. Refactor Capital 470. Salesforce 490. SFPIFPIM
451. Reneo Capital Management 471. Samsung Electronics 491. SGInnovate
452. Renren Inc. 472. Sanabil 492. Shangbay Capital
453. Rev1 Ventures 473. Sanofi 493. Shasta Ventures

Deep Knowledge Analytics 116

 600 Investors - AI for Drug Discovery and Advanced R&D
494. Shengding Equity Investment Fund 514. Sound Ventures 534. Synetro Group
495. Shunwei Capital 515. SPARK Impact 535. T. Rowe Price
496. Siemens 516. SpringRock Ventures 536. Tamarind Hill
497. Sierra Ventures 517. Square 1 Bank 537. Tavistock Group
498. Silicon Badia 518. SR One 538. TCP Venture Capital
499. Silicon Valley Bank 519. Stage Venture Partners 539. Team Builder Ventures
500. Singularity University Ventures 520. Stanford University Venture Fund 540. Techammer
501. Sinopharm Capital 521. Starlight Ventures 541. Techstars
502. Sinovation Ventures 522. Start Capital 542. TECHU
503. Sixty Degree Capital 523. StartUp Health 543. Temasek Holdings
504. Sky Ventures Group 524. Startupbootcamp 544. Tencent Holdings
505. Slow Ventures 525. StartX (StanfordStartX Fund) 545. TenOneTen Ventures
506. Smedvig Capital 526. Stripes 546. Terra Magnum Capital Partners
507. Sofinnova Partners 527. Summit Partners 547. The Cedars-Sinai Accelerator
508. SoftBank 528. Susa Ventures 548. The Column Group
509. Softbank Ventures Asia 529. Susquehanna International Group (SIG) 549. The Family
510. SoftBank Vision Fund 530. Sustainable Conversion Ventures 550. The Index Project
511. Soma Capital 531. SV Angel 551. The Longevity Fund
512. Sorrento Therapeutics 532. SV Tech Ventures 552. The Thiel Foundation
513. SOSV 533. Swisscom Ventures 553. Third Kind Venture Capital

Deep Knowledge Analytics 117

 600 Investors - AI for Drug Discovery and Advanced R&D
554. Third Rock Ventures 574. Universal Materials Incubator 593. Walking Ventures
555. TiE Angels 575. University of Birmingham 594. Washington Research Foundation
556. TIS Japan 576. Unshackled Ventures 595. Wavemaker Partners
557. Trancos Ventures 577. UpHonest Capital 596. Wellington Management
558. Travis May 578. Upsher Smith Laboratories 597. Western Technology Investment
559. Tribeca Venture Partners 579. Vanguard Atlantic 598. White Cloud Capital
560. Trinitas Capital 580. Varian 599. WI Harper Group
561. True Ventures 581. Velocity.Partners 600. Wild Basin Investments
562. Truffle Capital 582. VenBio Partners 601. Woodford Investment Management
563. TSVC 583. Versant Ventures 602. WorldQuant Ventures LLC
564. Tuesday 584. Vertex Ventures 603. Wren Capital
565. Two River 585. Vertex Ventures Israel 604. WuXi AppTec
566. Two Sigma Ventures 586. Vertex Ventures Southeast Asia & India 605. WuXi Healthcare Ventures
567. uBiome 587. VI Partners 606. Y Combinator
568. UCB Pharma 588. Viking Global Investors 607. Yael Capital Management Limited
569. UK Innovation & Science Seed Fund 589. Village Global 608. YF Capital (Yunfeng Capital)
570. UL Ventures 590. VisVires New Protein 609. Yitu Technology
571. Uncommon Denominator 591. Vives Fund 610. ZebiAI
572. Uni-Innovate Group 592. Walden Riverwood Ventures 611. ZhenFund
573. UnitedHealthcare Accelerator Powered 612. Zhongyuan Union Cell & Gene Eng
by Techstars

Deep Knowledge Analytics 118

 30 Pharma Corporations Applying AI for Drug Discovery

COMPANY NAME BASED IN WEBSITE

1. AbbVie United States abbvie.com

2. Agios Pharmaceuticals United States agios.com

3. Amgen United States amgen.com

4. Astellas Pharma Japan astellas.com

5. Astrazeneca United Kingdom astrazeneca.com

6. Bayer Germany bayer.com

7. Biogen United States biogen.com

8. Boehringer Ingelheim Germany boehringer-ingelheim.com

9. Bristol-Myers Squibb United States bms.com

10. Celgene United States celgene.com

11. Ilumina United States illumina.com

12. Ipsen France ipsen.com

13. Janssen Pharmaceuticals Belgium janssen.com

14. Johnson & Johnson United States jnj.com

15. Merck United States merck.com

Deep Knowledge Analytics 119

 30 Pharma Corporations Applying AI for Drug Discovery

COMPANY NAME BASED IN WEBSITE

16. Mitsubishi Tanabe Pharma Japan https://www.mt-pharma.co.jp/

17. Novartis Switzerland novartis.com

18. Novo Nordisk Denmark novonordisk.com

19. Daewoong Pharmaceutical South Korea daewoong.com

20. Evotec Germany evotec.com

21. Genentech United States gene.com

22. Gilead Sciences United States gilead.com

23. GSK United Kingdom gsk.com

24. Pfizer United States pfizer.com

25. Roche Switzerland roche.com

26. Sanofi France m-en.sanofi.com

27. Santen Japan santen.com

28. Sumitomo Dainippon Pharma Japan ds-pharma.com

29. Takeda Japan takeda.com

30. Teva Pharmaceutical Israel tevapharm.com

Deep Knowledge Analytics 120

 15 Chemical Corporations Applying AI in Healthcare

COMPANY NAME BASED IN WEBSITE

1. Asahi Kasei Japan asahi-kasei.co.jp

2. BASF Germany basf.com
3. COVESTRO Germany covestro.com
4. DIC Japan dic-global.com
5. The Dow Chemical Company United States dow.com
6. DSM The Netherlands dsm.com
7. DUPONT United States dupont.com
8. ECOLAB United States de-at.ecolab.com
9. EVONIK INDUSTRIES Germany corporate.evonik.de
10. Henkel Germany henkel.com
11. Lonza Switzerland lonza.com
12. MITSUI CHEMICALS Japan mitsuichem.com
13. Solvay Belgium solvay.de
14. SUMITOMO CHEMICAL Japan sumitomo-chem.co.jp
15. SYNGENTA Switzerland syngenta.com

Deep Knowledge Analytics 121

 25 Tech Corporations Applying Advanced AI in Healthcare

COMPANY NAME BASED IN WEBSITE

1. Adobe United States adobe.com

2. Alibaba China alibaba.com
3. Amazon United States amazon.com
4. Apple United States apple.com
5. Baidu China baidu.com
6. Canon United States usa.canon.com
7. Cisco United States cisco.com
8. Dell Technologies United States delltechnologies.com
9. Foxconn Technology Taiwan foxconn.com
10. Fujitsu Japan fujitsu.com
11. Google United States google.com
12. Hitachi Japan hitachi.com
13. Huawei China huawei.com
14. IBM United States ibm.com
15. Intel United States intel.com

Deep Knowledge Analytics 122

 25 Tech Corporations Applying Advanced AI in Healthcare

COMPANY NAME BASED IN WEBSITE

16. Microsoft United States microsoft.com

17. Nvidia United States nvidia.com

18. Oracle United States oracle.com

19. Salesforce United States salesforce.com

20. SAP Germany sap.com

21. Samsung Electronics South Korea samsung.com

22. Siemens Germany siemens.com

23. Tencent China tencent.com

24. Unisys United States unisys.com

25. Workday United States workday.com

Deep Knowledge Analytics 123

 20 CROs AI in Healthcare
COMPANY NAME BASED IN WEBSITE

1. Aptuit Italy aptuit.com

2. BioClinica United States bioclinica.com
3. Charles River Laboratories United States criver.com
4. CMIC United States en.cmicgroup.com
5. Covance China covance.com
6. Galapagos NV Belgium glpg.com
7. ICON United States iconplc.com
8. IonsGate Canada ionsgate.com
9. IQVIA United States iqvia.com
10. Iris Pharma France iris-pharma.com
11. J-STAR Research, Inc. / Porton United States jstar-research.com
12. Open Orphan plc Ireland openorphan.com
13. PAREXEL United States parexel.com
14. Phastar Great Britain phastar.com
15. Phlexglobal Great Britain phlexglobal.com
16. PPD United States ppd.com
17. PRA International United States prahs.com
18. SGS Switzerland sgs.com
19. Synsight France synsight.net
20. WuXi AppTec China wuxiapptec.com
Deep Knowledge Analytics 124
Overview of
Proprietary Analytics by
Deep Pharma Intelligence
 About Deep Pharma Intelligence

Deep Pharma Intelligence is producing regular analytical reports on major areas of high-potential in the pharmaceutical and healthcare industries,
maintaining ratings of companies and governments based on their innovation potential and business activity in the BioTech space, and providing
strategic consulting and investment intelligence services to top-tier clients, including major investment funds and banks, family offices, insurance
companies, government organizations, and big pharma companies among others. The company is a joint venture between the two highly specialized
UK-based market intelligence hubs in Pharma / BioTech space:

Pharma Division of Deep Knowledge Analytics (PD-DKA), a specialized BPT Analytics (BiopharmaTrend) - a rapidly growing analytical portal and
subsidiary of Deep Knowledge Analytics (DKA), the leading analytical media resource, dedicated to tracking emerging companies
entity specifically focused on deep intelligence of the high-potential areas (startups/scaleups), innovations, investments, and trends in the pharma
in the pharma industry, including artificial intelligence (AI) for drug and biotech space.
discovery sector.
BiopharmaTrend’s reports and articles were referenced by Deloitte,
Deep Knowledge Analytics Pharma Division serves as the main source of Forbes, and other high profile media and consulting companies.
investment intelligence and analytics for AI-Pharma, a specialized index
BiopharmaTrend is a media partner to a number of top-tier conferences
hedge fund for the AI in the drug discovery sector. PD-DKA’s insights are
and symposia in preclinical and clinical research, and healthcare research.
frequently covered by top media such as Forbes and the Financial Times,
and are acknowledged by top pharma executives.
Recently, MIT named this division a top technology think-tank,
acknowledging the AI ranking framework it developed.

Deep Pharma Intelligence 126

 Overview of Proprietary Analytics by
Pharma Division of Deep Pharma Analytics

Services:
Deep Pharma Intelligence (DPI) is a strategic partner to the
● Investment landscape profiling, identifying investment ideas in
leading Life Science organizations, investment institutions
the biotech/healthcare tech space.
(VC funds, investment banks), and governments across the
globe -- in matters related to investments, strategic ● Preliminary due-diligence (business, science and technology,
positioning, and policy development in the areas of intellectual property (IP) profiling, freedom of operation
pharmaceutical and biotech research, and healthcare tech. assessment, legal assessment etc).
While Deep Pharma Intelligence is regularly producing ● Comprehensive due-diligence (deep business, science and
open industry reports covering high-growth sectors in the technology assessment, IP and legal assessment, growth
Life Sciences, including artificial intelligence (AI), digital potential assessment etc).
health, and new therapies, some of the more in-depth
● Infringement analysis of technology (i.g. If you plan to partner or
research is only available to our clients and strategic
invest in a data-analytics biotechs, or AI-development vendors, it
partners under the “Proprietary Analytics” category.
is essential to understand their technological assets, both in
Our range of proprietary services includes custom terms of innovation potential and in terms of legal protection
consulting projects, based on the specific customer needs, and non-infringement risk management).
as well as a collection of pre-produced “ready-to-use”
● SWOT analysis of companies and technological sectors,
proprietary reports, produced by our research team,
competitive profiling.
covering general trends and specific action ideas and
strategy insights related to the most promising investment ● Industry profiling and growth strategy development for top-tier
prospects (e.g. new technologies, biotech startups), M&A companies and governments.
prospects (e.g. pipeline development targets), and
strategic growth ideas (trends profiling, industry overviews
etc).

Deep Pharma Intelligence 127

 Overview of Proprietary Analytics by
Pharma Division of Deep Pharma Analytics

The value our reports can deliver:

● Deep analysis of the deal-making prospects in the biotech and
healthcare tech space, identification of top mini-trends and larger
Proprietary Reports tendencies in innovations and technology adoption (e.g. AI,
blockchain, eHealth tech, longevity biomarkers, new therapeutics and
There are a few 40+ page reports delivering
therapies etc.);
practical answers to these specific questions in
order to optimize the short and long-term ● Tangible forecasts on the 3-5 years horizon, providing an overview of
strategies of biopharma corporations and other future scenarios of the development of various technologies in the
institutions related to the industry, with a newly pharma industry;
updated edition being released each quarter,
● Practical guides for adopting various technological solutions and best
incrementally increasing the precision,
practises, vendor profiling and contract research strategy building;
practicality and actionability of its technological
and financial analysis. ● Analysis of key market players in the emerging and high-growth areas
of the pharmaceutical and biotech industries.
Our reports are supported by our rapidly
developing data mining engine, data visualization The parties who gain early access to these reports will have deep expertise
platform and analytics dashboards. on how their strategic agendas can be optimized in order to leverage novel
research, new technologies, and emerging market opportunities, and stay
competitive in a rapidly-changing technological environment, and taking
into account shifting global priorities and trends.

Deep Pharma Intelligence 128

 Deep Pharma Intelligence:
Upcoming Projects and Analytical Tools

3D Visualisation Prototypes

Deep Pharma Intelligence Big Data Analytics Dashboard

Deep Pharma Intelligence 129

 www.deep-pharma.tech
DEEP
PHARMA
INTELLIGENCE

Link to the Report: deep-pharma.tech/landscape-overview

E-mail: [email protected] Website: deep-pharma.tech

Deep Pharma Intelligence (DKA) Disclaimer.

The information and opinions in this report were prepared by Deep Pharma Intelligence. The information herein is believed by DKA to be reliable but DKA makes no representation as to the accuracy or completeness of
such information. There is no guarantee that the views and opinions expressed in this communication will come to pass. DKA may provide, may have provided or may seek to provide advisory services to one or more
companies mentioned herein. In addition, employees of DKA may have purchased or may purchase securities in one or more companies mentioned in this report. Opinions, estimates and analyses in this report
constitute the current judgment of the author as of the date of this report. They do not necessarily reflect the opinions of DKA and are subject to change without notice. DKA has no obligation to update, modify or
amend this report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, estimate, forecast or analysis set forth herein, changes or subsequently becomes inaccurate. This
report is provided for informational purposes only. It is not to be construed as an offer to buy or sell or a solicitation of an offer to buy or sell any financial instruments or to participate in any particular trading strategy in
any jurisdiction.